

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

**IN RE: INSULIN PRICING
LITIGATION**

**Case No. 2:23-md-3080 (BRM)(RLS)
MDL No. 3080**

**JUDGE BRIAN R. MARTINOTTI
JUDGE RUKHSANAH L. SINGH**

**THIS DOCUMENT RELATES TO: 2:24-CV-11220
2:24-CV-11298
2:24-CV-11331
2:24-CV-11334
(SELF-FUNDED PAYERS TRACK)**

NOTICE OF MOTION FOR ENTRY OF ORDER TO SHOW CAUSE

TO: All Persons on ECF Service List

COUNSEL:

PLEASE TAKE NOTICE that Defendants Eli Lilly and Company; Novo Nordisk Inc.; Sanofi-Aventis U.S. LLC; CVS Pharmacy, Inc.; Caremark Rx, LLC; Caremark LLC; CaremarkPCS Health, LLC; Express Scripts, Inc.; Express Scripts Administrators, LLC; Medco Health Solutions, Inc.; ESI Mail Pharmacy Services, Inc.; Express Scripts Pharmacy, Inc.; and OptumRx, Inc. (collectively “Defendants”), by and through their respective undersigned counsel, shall move before the Honorable Rukhsanah L. Singh, U.S.M.J., at a date and time to be determined by the Court, at the United States District Court for the District of New Jersey, 402 East State Street, Trenton, New Jersey, for an Order, pursuant to Case

Management Order No. 14 ¶ 5(c), to Show Cause why Plaintiffs' cases should not be dismissed.

PLEASE TAKE FURTHER NOTICE that a proposed form of Order is submitted herewith.

Dated: March 6, 2025

/s/ Brian W. Carroll

McCARTER & ENGLISH, LLP

Brian W. Carroll
Four Gateway Center
100 Mulberry St.
Newark, NJ 07102
(973) 639-2020

DAVIS POLK & WARDWELL LLP

James P. Rouhandeh (*pro hac vice*)
David B. Toscano (*pro hac vice*)
450 Lexington Ave.
New York, NY 10017
(212) 450-4000

DAVIS POLK & WARDWELL LLP

Neal A. Potischman (*pro hac vice*)
Andrew Yaphe (*pro hac vice*)
1600 El Camino Real
Menlo Park, CA 94025
(650) 752-2000

*Attorneys for Defendant Novo Nordisk
Inc.*

Respectfully submitted,

/s/ Liza M. Walsh

WALSH PIZZI O'REILLY

FALANGA LLP

Liza M. Walsh
Katelyn O'Reilly
Three Gateway Center
100 Mulberry St., 15th floor
Newark, NJ 07102
(973) 757-1100

JONES DAY

Michael R. Shumaker (*pro hac vice*)
Julie E. McEvoy (*pro hac vice*)
William D. Coglianesi (*pro hac vice*)
Melissa Lim Patterson (*pro hac vice*)
51 Louisiana Ave. NW
Washington, DC 20001
(202) 879-3939

*Attorneys for Defendant Sanofi-
Aventis U.S. LLC*

/s/ Melissa A. Geist

REED SMITH LLP

Melissa A. Geist

Julia A. López

506 Carnegie Center, Suite 300

Princeton, NJ 08540

(609) 514-5978

KIRKLAND & ELLIS LLP

James F. Hurst (*pro hac vice*)

Andrew A. Kassof (*pro hac vice*)

Robert B. Ellis (*pro hac vice*)

Diana M. Watral (*pro hac vice*)

Ryan Moorman (*pro hac vice*)

Jason A. Feld (*pro hac vice*)

333 West Wolf Point Plaza

Chicago, IL 60654

(312) 862-2000

*Attorneys for Defendant Eli Lilly and
Company*

/s/ Brian Boone

O'TOOLE SCRIVO, LLC

Thomas P. Scrivo

Young Yu

14 Village Park Road

Cedar Grove, NJ 07009

T: (973) 239-5700

ALSTON & BIRD LLP

Brian D. Boone

1120 S. Tyron St., Ste. 300

Charlotte, NC 28203

T: (704) 444-1000

brian.boone@alston.com

ALSTON & BIRD LLP

Elizabeth Broadway Brown

1201 W. Peachtree St. NW, Ste. 4900

Atlanta, GA 30309

T: (404) 881-7000

liz.brown@alston.com

ALSTON & BIRD LLP

Kelley Connolly Barnaby

950 F. Street, NW

Washington, D.C. 20004

T: (202) 239-3300

kelley.barnaby@alston.com

Attorneys for Defendant OptumRx, Inc.

/s/ Jason R. Scherr

**MORGAN, LEWIS & BOCKIUS
LLP**

Jason R. Scherr

Patrick A. Harvey

Lindsey T. Levy

1111 Pennsylvania Avenue, NW

Washington, DC 20004

jr.scherr@morganlewis.com

patrick.harvey@morganlewis.com

lindsey.levy@morganlewis.com

Tel: (202) 739-3000

Attorneys for Defendants Express

Scripts, Inc.; Express Scripts

Administrators, LLC; ESI Mail

Pharmacy Services, Inc.; Express

Scripts Pharmacy, Inc.; and Medco

Health Solutions, Inc.

/s/ Benjamin Hazelwood

**MARINO, TORTORELLA & BOYLE,
P.C.**

Kevin H. Marino
John D. Tortorella
437 Southern Boulevard
Chatham, New Jersey 07928
T: (973) 824-9300
F: (973) 824-8425
kmarino@khmarino.com
jtortorella@khmarino.com

WILLIAMS & CONNOLLY LLP

Enu Mainigi
Craig Singer
R. Kennon Poteat III
A. Joshua Podoll
Benjamin Hazelwood
Daniel Dockery
680 Maine Avenue, S.W.
Washington, D.C. 20024
T: (202) 434-5000
F: (202) 434-5029
emainigi@wc.com
csinger@wc.com
kpoteat@wc.com
apodoll@wc.com
bhazelwood@wc.com
ddockery@wc.com

*Attorneys for Defendants CVS Pharmacy,
Inc.; Caremark Rx, LLC; Caremark LLC;
CaremarkPCS Health, LLC; and
Caremark, LLC*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

**IN RE: INSULIN PRICING
LITIGATION**

**Case No. 2:23-md-3080 (BRM)(RLS)
MDL No. 3080**

**JUDGE BRIAN R. MARTINOTTI
JUDGE RUKHSANAH L. SINGH**

**THIS DOCUMENT RELATES TO: 2:24-CV-11220
2:24-CV-11298
2:24-CV-11331
2:24-CV-11334
(SELF-FUNDED PAYERS TRACK)**

MOTION FOR ENTRY OF ORDER TO SHOW CAUSE

TO THE HONORABLE COURT:

NOW COME Defendants Eli Lilly and Company; Novo Nordisk Inc.; Sanofi-Aventis U.S. LLC; CVS Pharmacy, Inc.; Caremark Rx, LLC; Caremark LLC; CaremarkPCS Health, LLC; Express Scripts, Inc.; Express Scripts Administrators, LLC; Medco Health Solutions, Inc.; ESI Mail Pharmacy Services, Inc.; Express Scripts Pharmacy, Inc.; and OptumRx, Inc. (collectively “Defendants”), through their undersigned attorneys, and respectfully submit this Motion for Entry of an Order to Show Cause pursuant to Case Management Order No. 14 (“CMO 14”) ¶ 5(c)(i) (Dkt. 315). A proposed Order to Show Cause is attached hereto as **Exhibit A**.

Four Plaintiffs¹—all represented by Frantz Law Group, APLC—failed to serve executed Plaintiff Fact Sheets (“PFS”) within the time required by CMO 14 or any agreed extension. Pursuant to CMO 14 ¶ 5(c)(i), Defendants move this Court to issue an Order to Show Cause why these four Plaintiffs’ cases should not be dismissed in their entirety.

¹ “Plaintiffs” refers to Brick Township Public Schools (2:24-cv-11220), Waverly Community Schools (2:24-cv-11298), Traverse City Area Public Schools (2:24-cv-11331), and Hillsdale Community Schools (2:24-cv-11334). Defendants group these Plaintiffs together according to their shared counsel pursuant to CMO 14 ¶ 5(c)(1).

I. BACKGROUND

This Court ordered “[e]ach Plaintiff in the Self-Funded Payer Track” to “complete and provide documents responsive to the PFS” by a specified deadline. CMO 14 ¶ 1(a). By requiring disclosure of each plaintiff’s individual facts, the Court and the parties hoped to “mov[e] discovery ... in an efficient manner” and “narrow[] the issues and/or cases for prioritization or further proceedings.” ECF 291 at 2, 9. If a plaintiff fails to serve its PFS response by the required deadline, the Court stated that Defendants may serve a Notice of Failure to Serve and, after 14 days, move for an Order to Show Cause. *Id.* ¶ 5(c)(i). If a plaintiff still fails to serve the PFS by the deadline under that Order, its complaint shall be dismissed. *Id.* ¶ 5(c)(ii).

Pursuant to CMO 14, each of the four Plaintiffs was required to serve an executed PFS by February 18, 2025. None served PFS responses by their deadline, nor did any request an extension. Accordingly, Defendants served Notices of Failure to Serve pursuant to CMO 14 ¶ 5(b)(i) on February 19, 2025. *See* Exs. B-E. Each Notice was served via email to Plaintiffs’ attorney of record, William B. Shinoff of Frantz Law Group, with a courtesy copy to the Co-Lead Counsel’s designees, David Buchanan of Seeger Weiss; Brandon Bogle of Levin Papantonio; and Benjamin Widlanski of Kozyak Tropin & Throckmorton. Plaintiffs still have not served their PFS responses. *See* CMO 14 ¶ 5(b)(ii).

II. ARGUMENT

Pursuant to CMO 14 ¶ 5(c), this Court should issue an Order to Show Cause requiring Plaintiffs to serve their PFS within 14 days. The CMO is clear.

A prompt Order setting that 14-day deadline is particularly warranted because these Plaintiffs' failures to serve are part of a much broader pattern of disregard for the Court's PFS Orders. These four Plaintiffs are all represented by Frantz Law Group. Frantz and its referral partners have marketed to potential clients to file complaints in this litigation with promises that they "will not have to testify," "appear in court," or "participate in depositions," and that the PFS itself will take "only a few hours of staff time" to complete.² Unsurprisingly, not only have plaintiffs represented by Frantz repeatedly missed PFS deadlines, every PFS these plaintiffs have served is woefully incomplete. Many Frantz clients are producing no documents, failing to answer broad sections of the PFS (including questions seeking basic information about the plaintiffs themselves or allegations central to their complaints), and providing boilerplate responses copied from other plaintiffs' PFS.

² See, e.g., ECF 269-5 ("All that will be required as part of this litigation is to complete a court order discovery questionnaire which should take only a few hours of staff time."); Dexter Community Schools, *BOE Meeting 9-23-2024*, YOUTUBE at 1:20:19 (Sept. 23, 2024), https://www.youtube.com/watch?v=KnLtcf9r_QM&t=4637s ("So, we as a district, if we choose to join this, will not have to testify ..."); Thrun Law Firm, P.C., *Letter to Retainer Client re Insulin Litigation*, BARRY COUNTY BOARD OF COMMISSIONERS at 15 (Aug. 20, 2024), <https://www.barrycounty.org/COW%20packet%2011-19-24.pdf>.

See, e.g., Ex. F, Stockbridge Community Schools, 2:24-cv-11216, PFS at Questions 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 29, 30, 31, 32, 33; Ex. G, Talbot County Public Schools, 2:24-cv-11142, PFS at Questions 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 31, 32, 33, 35.

These are all issues Defendants intend to separately bring to the Court. For now, Defendants respectfully ask the Court to enforce CMO 14 by requiring these four Plaintiffs represented by Frantz to promptly serve their PFS within 14 days, or have their complaints dismissed. *See* CMO 14 ¶ 5(c)(i).

III. CONCLUSION

Defendants respectfully request that the Court enter an Order to Show Cause with a 14-day deadline as to the four Plaintiffs that failed to serve an executed PFS pursuant to CMO No. 14 ¶ 5(c).

Dated: March 6, 2025

/s/ Brian W. Carroll

McCARTER & ENGLISH, LLP

Brian W. Carroll
Four Gateway Center
100 Mulberry St.
Newark, NJ 07102
(973) 639-2020

DAVIS POLK & WARDWELL LLP

James P. Rouhandeh (*pro hac vice*)
David B. Toscano (*pro hac vice*)
450 Lexington Ave.
New York, NY 10017
(212) 450-4000

DAVIS POLK & WARDWELL LLP

Neal A. Potischman (*pro hac vice*)
Andrew Yaphe (*pro hac vice*)
1600 El Camino Real
Menlo Park, CA 94025
(650) 752-2000

*Attorneys for Defendant Novo Nordisk
Inc.*

Respectfully submitted,

/s/ Liza M. Walsh

WALSH PIZZI O'REILLY

FALANGA LLP
Liza M. Walsh
Katelyn O'Reilly
Three Gateway Center
100 Mulberry St., 15th floor
Newark, NJ 07102
(973) 757-1100

JONES DAY

Michael R. Shumaker (*pro hac vice*)
Julie E. McEvoy (*pro hac vice*)
William D. Coglianese (*pro hac vice*)
Melissa Lim Patterson (*pro hac vice*)
51 Louisiana Ave. NW
Washington, DC 20001
(202) 879-3939

*Attorneys for Defendant Sanofi-
Aventis U.S. LLC*

/s/ Melissa A. Geist

REED SMITH LLP

Melissa A. Geist

Julia A. López

506 Carnegie Center, Suite 300

Princeton, NJ 08540

(609) 514-5978

KIRKLAND & ELLIS LLP

James F. Hurst (*pro hac vice*)

Andrew A. Kassof (*pro hac vice*)

Robert B. Ellis (*pro hac vice*)

Diana M. Watral (*pro hac vice*)

Ryan Moorman (*pro hac vice*)

Jason A. Feld (*pro hac vice*)

333 West Wolf Point Plaza

Chicago, IL 60654

(312) 862-2000

*Attorneys for Defendant Eli Lilly and
Company*

/s/ Brian Boone

O'TOOLE SCRIVO, LLC

Thomas P. Scrivo
Young Yu
14 Village Park Road
Cedar Grove, NJ 07009
T: (973) 239-5700

ALSTON & BIRD LLP

Brian D. Boone
1120 S. Tyron St., Ste. 300
Charlotte, NC 28203
T: (704) 444-1000
brian.boone@alston.com

ALSTON & BIRD LLP

Elizabeth Broadway Brown
1201 W. Peachtree St. NW, Ste. 4900
Atlanta, GA 30309
T: (404) 881-7000
liz.brown@alston.com

ALSTON & BIRD LLP

Kelley Connolly Barnaby
950 F. Street, NW
Washington, D.C. 20004
T: (202) 239-3300
kelley.barnaby@alston.com

Attorneys for Defendant OptumRx, Inc.

/s/ Jason R. Scherr

**MORGAN, LEWIS & BOCKIUS
LLP**

Jason R. Scherr
Patrick A. Harvey
Lindsey T. Levy
1111 Pennsylvania Avenue, NW
Washington, DC 20004
jr.scherr@morganlewis.com
patrick.harvey@morganlewis.com
lindsey.levy@morganlewis.com
Tel: (202) 739-3000

*Attorneys for Defendants Express
Scripts, Inc.; Express Scripts
Administrators, LLC; ESI Mail
Pharmacy Services, Inc.; Express
Scripts Pharmacy, Inc.; and Medco
Health Solutions, Inc.*

/s/ Benjamin Hazelwood

**MARINO, TORTORELLA & BOYLE,
P.C.**

Kevin H. Marino
John D. Tortorella
437 Southern Boulevard
Chatham, New Jersey 07928
T: (973) 824-9300
F: (973) 824-8425
kmarino@khmarino.com
jtortorella@khmarino.com

WILLIAMS & CONNOLLY LLP

Enu Mainigi
Craig Singer
R. Kennon Poteat III
A. Joshua Podoll
Benjamin Hazelwood
Daniel Dockery
680 Maine Avenue, S.W.
Washington, D.C. 20024
T: (202) 434-5000
F: (202) 434-5029
emainigi@wc.com
csinger@wc.com
kpoteat@wc.com
apodoll@wc.com
bhazelwood@wc.com
ddockery@wc.com

*Attorneys for Defendants CVS Pharmacy,
Inc.; Caremark Rx, LLC; Caremark LLC;
CaremarkPCS Health, LLC; and
Caremark, LLC*

Exhibit A

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

**IN RE: INSULIN PRICING
LITIGATION**

**Case No. 2:23-md-3080 (BRM)(RLS)
MDL No. 3080**

**JUDGE BRIAN R. MARTINOTTI
JUDGE RUKHSANAH L. SINGH**

**THIS DOCUMENT RELATES TO: 2:24-CV-11220
2:24-CV-11298
2:24-CV-11331
2:24-CV-11334
(SELF-FUNDED PAYERS TRACK)**

PROPOSED ORDER TO SHOW CAUSE

THIS MATTER having come before the Court upon the Motion of Eli Lilly and Company; Novo Nordisk Inc.; Sanofi-Aventis U.S. LLC; CVS Pharmacy, Inc.; Caremark Rx, LLC; Caremark LLC; CaremarkPCS Health, LLC; Express Scripts, Inc.; Express Scripts Administrators, LLC; Medco Health Solutions, Inc.; ESI Mail Pharmacy Services, Inc.; Express Scripts Pharmacy, Inc.; and OptumRx, Inc. (collectively “Defendants”) for Entry of an Order to Show Cause, and the Court having read and considered the Parties’ submissions, and good and sufficient cause having been shown,

IT IS on this ____ day of _____, _____, **HEREBY ORDERED** that Plaintiff tender a completed PFS as required by CMO 14 on or before the ____ day

of _____, _____. Pursuant to CMO 14 ¶ 5(c), Plaintiff's failure to do so shall result in dismissal of Plaintiff's complaint without prejudice absent further order of the Court. If Plaintiff fails to move for reinstatement within 30 days of dismissal, its case will be dismissed with prejudice with further order of the Court.

HONORABLE RUKHSANAH L. SINGH
United States Magistrate Judge

Exhibit B

From: Walling, Kate
Sent: Wednesday, February 19, 2025 8:48 PM
To: kwestphal@frantzlawgroup.com; WShinoff@frantzlawgroup.com; regina@frantzlawgroup.com; host@frantzlawgroup.com; bbogle@levinlaw.com; dbuchanan@seegerweiss.com; bwidlanski@kttlaw.com
Cc: Kearney, Ryan; Stilley, Tyler; Feld, Jason Adam; Moorman, Ryan
Subject: Brick Township Public Schools v. Eli Lilly and Company et al., 2:24-cv-11220-BRM-RLS || Notice of Failure to Serve

Counsel,

Brick Township Public Schools' plaintiff fact sheet and related production was due on February 18, 2025. See ECF No. 315 ¶ 1(a)(iii) (CMO No. 14). To date, we have not received either, and are therefore notifying you of a failure to serve pursuant to CMO No. 14 ¶ 5(b). Please tender an executed and substantially completed PFS and production, or if Brick Township Public Schools in fact served a fact sheet and production on February 18, 2025, please advise us whom you served.

Best,

Kate Walling

KIRKLAND & ELLIS LLP

333 West Wolf Point Plaza, Chicago, IL 60654

T +1 312 862 3727 **M** +1 312 825 2771

F +1 312 862 2200

kate.walling@kirkland.com

Exhibit C

From: Walling, Kate
Sent: Wednesday, February 19, 2025 8:46 PM
To: kwestphal@frantzlawgroup.com; WShinoff@frantzlawgroup.com; regina@frantzlawgroup.com; host@frantzlawgroup.com; bbogle@levinlaw.com; dbuchanan@seegerweiss.com; bwidlanski@kttlaw.com
Cc: Feld, Jason Adam; Moorman, Ryan; Kearney, Ryan; Stilley, Tyler
Subject: Waverly Community Schools v. Eli Lilly and Company et al., 2:24-cv-11298-BRM-RLS || Notice of Failure to Serve

Counsel,

Waverly Community Schools' plaintiff fact sheet and related production was due on February 18, 2025. See ECF No. 315 ¶ 1(a)(iii) (CMO No. 14). To date, we have not received either, and are therefore notifying you of a failure to serve pursuant to CMO No. 14 ¶ 5(b). Please tender an executed and substantially completed PFS and production, or if Waverly Community Schools in fact served a fact sheet and production on February 18, 2025, please advise us whom you served.

Best,

Kate Walling

KIRKLAND & ELLIS LLP

333 West Wolf Point Plaza, Chicago, IL 60654

T +1 312 862 3727 **M** +1 312 825 2771

F +1 312 862 2200

kate.walling@kirkland.com

Exhibit D

From: Walling, Kate
Sent: Wednesday, February 19, 2025 8:44 PM
To: kwestphal@frantzlawgroup.com; WShinoff@frantzlawgroup.com; regina@frantzlawgroup.com; host@frantzlawgroup.com; bbogle@levinlaw.com; dbuchanan@seegerweiss.com; bwidlanski@kttlaw.com
Cc: Moorman, Ryan; Feld, Jason Adam; Kearney, Ryan; Stilley, Tyler
Subject: Traverse City Area Public Schools v. Eli Lilly and Company et al., 2:24-cv-11331-BRM-RLS || Notice of Failure to Serve

Counsel,

Traverse City Area Public Schools' plaintiff fact sheet and related production was due on February 18, 2025. See ECF No. 315 ¶ 1(a)(iii) (CMO No. 14). To date, we have not received either, and are therefore notifying you of a failure to serve pursuant to CMO No. 14 ¶ 5(b). Please tender an executed and substantially completed PFS and production, or if Traverse City Area Public Schools in fact served a fact sheet and production on February 18, 2025, please advise us whom you served.

Best,

Kate Walling

KIRKLAND & ELLIS LLP

333 West Wolf Point Plaza, Chicago, IL 60654

T +1 312 862 3727 **M** +1 312 825 2771

F +1 312 862 2200

kate.walling@kirkland.com

Exhibit E

From: Walling, Kate
Sent: Wednesday, February 19, 2025 8:48 PM
To: kwestphal@frantzlawgroup.com; WShinoff@frantzlawgroup.com; regina@frantzlawgroup.com; host@frantzlawgroup.com; bbogle@levinlaw.com; dbuchanan@seegerweiss.com; bwidlanski@kttlaw.com
Cc: Moorman, Ryan; Feld, Jason Adam; Kearney, Ryan; Stilley, Tyler
Subject: Hillsdale Community Schools v. Eli Lilly and Company et al., 2:24-cv-11325-BRM-RLS || Notice of Failure to Serve

Counsel,

Hillsdale Community Schools' plaintiff fact sheet and related production was due on February 18, 2025. See ECF No. 315 ¶ 1(a)(iii) (CMO No. 14). To date, we have not received either, and are therefore notifying you of a failure to serve pursuant to CMO No. 14 ¶ 5(b). Please tender an executed and substantially completed PFS and production, or if Hillsdale Community Schools in fact served a fact sheet and production on February 18, 2025, please advise us whom you served.

Best,

Kate Walling

KIRKLAND & ELLIS LLP

333 West Wolf Point Plaza, Chicago, IL 60654

T +1 312 862 3727 **M** +1 312 825 2771

F +1 312 862 2200

kate.walling@kirkland.com

Exhibit F

**IN THE UNITED STATES PLAINTIFF COURT
FOR THE PLAINTIFF OF NEW JERSEY**

IN RE: INSULIN PRICING LITIGATION

This document relates to:

Self-Funded Payer Track

**Case No. 2:23-md-03080 (BRM)(RLS)
MDL No. 3080**

**JUDGE BRIAN R. MARTINOTTI
JUDGE RUKHSANAH L. SINGH**

SELF-FUNDED PAYER PLAINTIFF FACT SHEET

Please provide the following information for each Plaintiff that is part of the Self-Funded Payer Track that has filed a complaint in *In Re: Insulin Pricing Litigation*, MDL No. 3080. In completing this Plaintiff Fact Sheet (“PFS”), You are under oath and must provide information that is true and correct to the best of Your knowledge, information, and belief. The scope of the questions herein and responses thereto will be limited to information and/or documents within each Your possession, custody, or control. To the extent a You lack information or documents in Your possession, custody, or control in response to the questions or document requests below, You shall expressly state You lack such information in Your response.

Do not leave any questions unanswered or blank. If You are filling out this PFS in hard copy, use additional sheets as needed to fully respond.

This PFS constitutes discovery responses subject to the Federal Rules of Civil Procedure. You must diligently investigate whether You have within Your possession, custody, or control information or documents responsive to the questions and requests, inclusive of custodial sources. (ECF No. 291 at 2.) To the extent You assert an undue burden in connection with a particular request in this PFS as to custodial files, You must meet and confer with Defendants and, if unresolved, present the issue to the Court for resolution. You may not rely on Rule 33(d) in responding to the PFS questions unless the question specifically allows production of documents in lieu of a response. You must promptly supplement Your responses if You learn that they are incomplete or inaccurate in any respect. Each question in this PFS is continuing in nature and requires supplemental answers as You obtain further information between completing this PFS and trial. Information provided will only be used for purposes related to this litigation and may be disclosed only as permitted by the Stipulated Confidentiality Order entered in this MDL proceeding. (See ECF No. 117.)

INSTRUCTIONS

1. None of the questions in this PFS seek privileged information. To the extent You believe that any form of privilege prevents You from fully answering a question, state Your basis

for withholding an answer or part of an answer on the grounds of privilege and which privilege You believe applies. If You assert that part of a question is objectionable or calls for privileged information, respond to the remaining parts of the question to which You do not object.

2. “And” and “or” mean “and/or” and should be construed conjunctively and disjunctively to require the broadest possible response. “Including” shall mean “including but not limited to.”

3. All definitions provided herein are limited to the use of the terms in these Requests.

DEFINITIONS

1. “Administrative Fees” means any fee paid by a manufacturer to a PBM in exchange for any administrative service the PBM performs.

2. “At-Issue Products” means the insulin products and any other pharmaceuticals that You identify in response to Question No. 10.

3. “Health Plan” means all health plans offered by, administered by, or sponsored by You during the Period that the Health Plan offered or included Prescription Drug Coverage.

4. “Out-of-Pocket Maximum” means the maximum amount of allowable costs or expenses that a person with any form of health insurance, health coverage, prescription drug plan, or any other health plan that helps enrollees pay for prescribed pharmaceuticals can incur during a given year through their health insurance.

5. “PBM” means pharmacy benefit manager.

6. “Prescription Drug Coverage” means any form of health insurance, health coverage, prescription drug plan, or any other health plan that helps enrollees pay for prescribed pharmaceutical drugs.

7. “Rebates” means any rebate, payment, discount, or other price concession made or paid by a manufacturer to a PBM.

8. “Time Period” means January 1, 2011 to January 1, 2023.

9. “WAC” means wholesale acquisition cost.

10. “You” or “Your” means the Plaintiff named in this Action and any other persons or entities on whose behalf the Plaintiff brings this action, including any official, department, agency, investigative unit, entity, or program.

Exhibit G

**IN THE UNITED STATES PLAINTIFF COURT
FOR THE PLAINTIFF OF NEW JERSEY**

IN RE: INSULIN PRICING LITIGATION

This document relates to:

Self-Funded Payer Track

**Case No. 2:23-md-03080 (BRM)(RLS)
MDL No. 3080**

**JUDGE BRIAN R. MARTINOTTI
JUDGE RUKHSANAH L. SINGH**

SELF-FUNDED PAYER PLAINTIFF FACT SHEET

Please provide the following information for each Plaintiff that is part of the Self-Funded Payer Track that has filed a complaint in *In Re: Insulin Pricing Litigation*, MDL No. 3080. In completing this Plaintiff Fact Sheet (“PFS”), You are under oath and must provide information that is true and correct to the best of Your knowledge, information, and belief. The scope of the questions herein and responses thereto will be limited to information and/or documents within each Your possession, custody, or control. To the extent a You lack information or documents in Your possession, custody, or control in response to the questions or document requests below, You shall expressly state You lack such information in Your response.

Do not leave any questions unanswered or blank. If You are filling out this PFS in hard copy, use additional sheets as needed to fully respond.

This PFS constitutes discovery responses subject to the Federal Rules of Civil Procedure. You must diligently investigate whether You have within Your possession, custody, or control information or documents responsive to the questions and requests, inclusive of custodial sources. (ECF No. 291 at 2.) To the extent You assert an undue burden in connection with a particular request in this PFS as to custodial files, You must meet and confer with Defendants and, if unresolved, present the issue to the Court for resolution. You may not rely on Rule 33(d) in responding to the PFS questions unless the question specifically allows production of documents in lieu of a response. You must promptly supplement Your responses if You learn that they are incomplete or inaccurate in any respect. Each question in this PFS is continuing in nature and requires supplemental answers as You obtain further information between completing this PFS and trial. Information provided will only be used for purposes related to this litigation and may be disclosed only as permitted by the Stipulated Confidentiality Order entered in this MDL proceeding. (See ECF No. 117.)

INSTRUCTIONS

1. None of the questions in this PFS seek privileged information. To the extent You believe that any form of privilege prevents You from fully answering a question, state Your basis

for withholding an answer or part of an answer on the grounds of privilege and which privilege You believe applies. If You assert that part of a question is objectionable or calls for privileged information, respond to the remaining parts of the question to which You do not object.

2. “And” and “or” mean “and/or” and should be construed conjunctively and disjunctively to require the broadest possible response. “Including” shall mean “including but not limited to.”

3. All definitions provided herein are limited to the use of the terms in these Requests.

DEFINITIONS

1. “Administrative Fees” means any fee paid by a manufacturer to a PBM in exchange for any administrative service the PBM performs.

2. “At-Issue Products” means the insulin products and any other pharmaceuticals that You identify in response to Question No. 10.

3. “Health Plan” means all health plans offered by, administered by, or sponsored by You during the Period that the Health Plan offered or included Prescription Drug Coverage.

4. “Out-of-Pocket Maximum” means the maximum amount of allowable costs or expenses that a person with any form of health insurance, health coverage, prescription drug plan, or any other health plan that helps enrollees pay for prescribed pharmaceuticals can incur during a given year through their health insurance.

5. “PBM” means pharmacy benefit manager.

6. “Prescription Drug Coverage” means any form of health insurance, health coverage, prescription drug plan, or any other health plan that helps enrollees pay for prescribed pharmaceutical drugs.

7. “Rebates” means any rebate, payment, discount, or other price concession made or paid by a manufacturer to a PBM.

8. “Time Period” means January 1, 2011 to January 1, 2023.

9. “WAC” means wholesale acquisition cost.

10. “You” or “Your” means the Plaintiff named in this Action and any other persons or entities on whose behalf the Plaintiff brings this action, including any official, department, agency, investigative unit, entity, or program.

QUESTIONS

I. CASE INFORMATION

1. Plaintiff: Talbot County Public Schools
2. Case name and caption number: In Re: Insulin Pricing Litigation Plaintiff v. Eli Lilly and Company et al.; Case No. 2:24-CV-11142
3. Name, firm, and e-mail of principal attorney(s) representing You: Frantz Law Group, APLC, wshinoff@frantzlawgroup.com
4. Defendants: Eli Lilly and Company, Sanofi-Aventus U.S. LLC, Novo Nordisk Inc., CVS Health Corporation, CVS Pharmacy, Inc. Caremark Rx LLC, Caremark LLC, CaremarkPCS Health, LLC, EverNorth Health, Inc., Express Scripts Inc., Express Scripts Administrators, LLC, Medco Health Solutions, Inc., ESI Mail Pharmacy Services, Inc., Express Scripts Pharmacy Inc., UnitedHealth Group, Inc., United Healthcare Services, Inc., UnitedHealthcare Insurance Co., Optum Inc., OptumRx, Inc. and OptumInsight, Inc.

II. BENEFICIARIES

5. In the table below, provide the total number of individuals enrolled in Your Health Plan, including primary and dependent beneficiaries, for each year of the Time Period:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Year	Number of Beneficiaries
2011	
2012	
2013	
2014	
2015	
2016	
2017	
2018	
2019	
2020	
2021	
2022	

6. Provide the total number of individuals who used Your Health Plan to purchase or use At-Issue Products during each year of the Time Period:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Year	Number of Purchasers/Users of At-Issue Products
2011	
2012	
2013	
2014	
2015	
2016	
2017	
2018	
2019	
2020	
2021	
2022	

III. PERSONS OR ENTITIES WITH RELEVANT KNOWLEDGE

7. In the form of the table below, identify the name, title, and dates of employment of Your current and former employees, representatives, or agents who had any responsibility over the design or administration of Your Health Plan or Prescription Drug Coverage during the Time Period, including responsibility over the decision to enter into agreements governing Prescription Drug Coverage, Rebates, Your Health Plan, and formularies:

Name	Title	Dates of Employment or Contract	Area(s) of Responsibility
Reginna Villers	Benefits Manager		Benefits
Zulieka Horsey	Asst. Superintendent of Admin. Services (HR)		HR

8. To the extent not included in response to Question No. 7 above, in the form of the table below, identify by name, title, and dates of employment Your current and former employees or representatives with knowledge regarding the allegations in Your Complaint:

Name	Title	Dates of Employment	Area(s) of Responsibility

9. In the form of the table below, identify by name any department, agency, investigative unit, entity, or other program with responsibility over functions related to the allegations in Your Complaint. Summarize each of those entities' area of responsibility:

Entity Name	Area of Responsibility
Bolton	Plan Administrator

IV. AT-ISSUE PRODUCTS

10. Identify every insulin or other pharmaceutical that You allege is relevant to any claim for damages or other relief You seek in this case (the "At-Issue Products"):¹

Humulin R, Humulin R 500, Novolin R, Humulin N, Humulin 70/30, Novolin N, Novolin 70/30, Humalog, Novolog, Apidra, Humalog 50/50, Humalog 75/25, Novolog 70/30, Lantus, Levemir, Basaglar (Kwikpen), Toujeo (Solostar), Tresiba, Trulicity (Dulaglutide), Mounjaro (Tirzepatide/GIP), Victoza (Liraglutide), Xultophy (insulin degludec/liraglutide), Ozempic (Semaglutide), Rybelsus (semaglutide tablets), Adylxin (lixisenatide), Soliqua (insulin glargine/lixisenatide)

11. In the form of the table below or through the production of documents, for each At-Issue Product, provide the total amount of money that You spent on the At-Issue Product for members enrolled in Your Health Plan for each year during the Time Period, and the total Rebates received by You:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

¹ In seeking this information, Defendants do not concede that any pharmaceuticals identified by You are relevant.

At-Issue Product	Year	Total Number of Scripts	Total Spent by You	Total Rebates Received

V. YOUR HEALTH PLANS

12. In the form of the table below, for each Health Plan that You offered that included Prescription Drug Coverage during the Time Period, identify the plan identification number, name, or other plan identifier and the starting and ending dates for each plan year during the Time Period:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Health Plan Identifier	Start Date	End Date

13. In the form of the table below, list all PBMs or other entities with whom You have contracted to administer Prescription Drug Coverage for every Health Plan identified in response to Question No. 12 for each plan year during the Time Period:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Health Plan Identifier	Plan Year	PBM or Other Entity

14. Identify all insurers or third-party administrators with whom You have contracted relating to the Health Plans identified in response to Question No. 12: N/A

VI. REBATES AND FEES

15. In the form of the table below, identify each contract You have or had with a PBM during the Time Period, including the party with which You contracted, and the year. Include in Your answer any addendums or other agreements You entered pursuant to an existing master agreement. If a contract was entered into before the Time Period began but did not expire until after the Time Period began, identify that contract as well:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Contract	Contracting Entity	Year(s)

16. Have You ever used preventative drug lists, critical drug affordability programs, or any other program to lower the out-of-pocket costs of the At-Issue Products for Your members?

_____ Yes _____ No

Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, in the form of the table below, identify each such Health Plan where You implemented such a program, the program, the year the program was implemented, and the applicable At-Issue Products:

Health Plan	Program	Year	At-Issue Product

17. Have You ever passed Rebates received from a PBM through to Your members at the point of sale for any of the At-Issue Products? _____ Yes _____ No _____ Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, in the form of the table below, identify each such Health Plan where You passed on Rebates, the years You passed on Rebates, the At-Issue Products for which You passed on Rebates, and the percentage of Rebates that You passed on to members at the point of sale:

Health Plan	Year Passed on Rebate	At-Issue Product	Percentage of Rebate Passed on

18. Other than passing Rebates through to Your members at the point of sale, describe the ways in which You use Rebates and Administrative Fees received from PBMs for At-Issue Products:

Unknown at this time but Plaintiff reserves the right to supplement this response.

19. In any contract identified in response to Question No. 15, did any other PBM or any other contracting entity submit bids/proposals? ____ Yes ____ No

Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, identify any entity submitting competing bids/proposals, and produce the competing bids:

20. During the relevant time period, did You contract with, or use master contracts from, any other entities (e.g., MMCAP) for rebates or other price concessions related to purchasing pharmaceutical products? ____ Yes ____ No

Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, in the form of the table below, identify each such contract, the contracting entity, the year, and the percentage of or other determinant of the Rebates the contracting entity agreed to pass through to You:

Contract	Contracting Entity	Year	Percentage of Rebates

VII. MISREPRESENTATIONS AND OMISSIONS

21. In the form of the table below, identify every specific misrepresentation that a Defendant allegedly made that forms the basis of the allegations in Your lawsuit, of which You are currently aware, including the approximate date, the source, who received the statement, the reason why You believe the statement was false, whether or not You relied on the

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
False list prices for each of the at-issue drugs	Throughout the relevant period	All public compendia (including Medi-Span, First DataBank, Redbook, etc.)	All payors, including the Plaintiff.	<i>The Astronomical Price of Insulin Hurts Am. Families</i> , RAND (Jan. 6, 2021) (“RAND Report”); <i>Drug Pricing Investigation: Majority Staff Report</i> , Comm. on Oversight & Reform, U.S. H.R. (Dec. 2021) (“ <i>Drug Pricing Investigation</i> ”); Comm. on Energy & Commerce, Mem., <i>Hearing on “Priced Out of</i>	Yes. The Plaintiff relied on the at-issue list prices each time it paid for an at-issue drug. Other payors, patients, and third parties also relied on the Manufacturers’ false prices.	Eli Lilly, Sanofi, Novo Nordisk

² The list of sources cited for each misrepresentation is not necessarily exhaustive. Where numerous sources support Plaintiff’s belief that a statement is false, Plaintiff has selected examples of authorities that support that belief. Other examples may be cited in Plaintiff’s Complaint or the entries in this chart addressing different misrepresentations, or may exist elsewhere.

³ No single source cited here was sufficient to put Plaintiff on notice of the Insulin Pricing Scheme described in the Complaint or the claims alleged therein. Plaintiff’s responses to the inquiries set forth in Section VIII (Timing of Awareness) describe when Plaintiff became aware of specific facts relating to the allegations in the Complaint.

⁴ Where named as Defendants, the PBM Defendants are identified by defendant group. “Express Scripts,” for example, refers to the Express Scripts family of defendants, including Evernorth Health, Inc.; Express Scripts, Inc.; Express Scripts Administrators, LLC; Medco Health Solutions, Inc.; ESI Mail Pharmacy Service, Inc.; and Express Scripts Pharmacy, Inc., and where Forms 10-K or other S.E.C. filings are at issue, occasionally non-defendant Cigna Corporation, which reports for these entities.

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				<i>a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin</i> ” (Apr. 5, 2019) (“ <i>Priced Out of a Lifesaving Drug</i> ”); U.S. H.R., <i>Drug Pricing Investigation: Industry Spending on Buybacks, Dividends and Executive Compensation</i> , at 3 (July 2021) (“ <i>Industry Spending Report</i> ”); Natalie Shure, <i>The Insulin Racket</i> , AMERICAN PROSPECT (June 24, 2019); Joanna Shepherd, <i>Pharmacy Benefit Managers, Rebates, and Drug Prices: Conflicts of Interest in the Market for Prescription Drugs</i> , YALE L. & POLICY REV., Vol. 38 (Jan. 2019) (prices bloated		

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				with rebates and mislabeled rebates).”; Adam Fein, <i>Tex. Shows Us Where PBMs’ Rebates Go</i> , DRUG CHANNELS (Aug. 9, 2022) (same); Eric Percher, <i>Trends in Profitability and Compensation of PBMs and PBM Contracting Entities</i> , Nephron Research (Sept. 18, 2023) (same). <i>See also</i> Senate Insulin Report at 41-46, 49-89; Broward Cnty., Fla., <i>Analysis of Broward Cnty.’s Prescription Drug Coverage</i> (Aug. 2019).		
False list prices as reflected in invoices Express Scripts and CVS issued to the Plaintiff.	Dates reflected on invoices, including, but not limited to, Other invoices PBM issued to the Plaintiff are	Routine invoices.	The Plaintiff.	See sources cited above.	Yes. The Plaintiff relied on the false invoiced price each time it paid for an at-issue drug.	All Defendants .

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
	no longer in its possession custody or control.					
Manufacturer Payments are “fees,” “credits,” “discounts,” and other categories of payment when they are, in fact, rebates.	Throughout the relevant period.	Routine invoices and other payors for the at-issue medications	The Plaintiff.	Shepherd, <i>supra</i> (PBMs “designate as much as twenty-five or thirty percent of the negotiated rebates as fees to avoid sharing the rebates.”); Fein, <i>supra</i> (the PBMs retained between 9% and 21% of all Manufacturer Payments between 2016 and 2021); Percher, <i>supra</i> (PBM compensation from rebates and other kickbacks doubled between 2018 and 2022, from \$3.8 billion to \$7.6 billion. “This growth was fueled by increases in traditional administrative fees as well as the emergence of new data and PBM contracting entity fees.”); <i>See also</i>	Yes. The Plaintiff and other payors rely on these representations.	OptumRx, Express Scripts, CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Broward County, Florida, Analysis, <i>supra</i> .		
Cigna provides “formulary management services” that “assist customers and physicians in choosing clinically-appropriate, cost-effective drugs and prioritize access, safety and affordability.”	Dec. 31, 2018 Dec. 31, 2019 Dec. 31, 2020 Dec. 31, 2021 Dec. 31, 2022 Dec. 31, 2023	Cigna Annual Report (Form 10-K) (FYE Dec. 31, 2018, Dec. 31, 2019, Dec. 31, 2020, Dec. 31, 2021, Dec. 31, 2022, Dec. 31, 2023.	S.E.C.; public statement	<i>See, e.g.,</i> RAND Report; Senate Insulin Report at 5-8, 29, 39, 40, 44, 51, 52, <i>et al.</i> ; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (Complaint ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (Complaint ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, <i>Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin</i> (Apr. 10, 2019); Adam Fein, <i>Five takeaways from the big three</i>	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				<i>PBM's' 2022 formulary exclusions</i> (Jan. 19, 2022).		
“OptumRx works directly with pharmaceutical manufacturers to secure discounts that lower the overall cost of medications and create tailored formularies—or drug lists—to ensure people get the right medications. [<i>UnitedHealth Group</i>] then negotiate[s] with pharmacies to lower costs at the point of sale”	Dec. 31, 2020	UnitedHealth Group 2020 Sustainability Report	Public statement	<i>See, e.g.,</i> RAND Report; Senate Insulin Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (Complaint ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin” (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	United Health Group/ OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
Express Scripts “saved [its] clients more than \$3 billion through the Express Scripts National Preferred Formulary.”	January 11, 2016	Tim Wentworth, Express Scripts, at the 34th annual JP Morgan Healthcare Conference	Public statement	See, e.g., RAND Report; Senate Insulin Report at 5-8, 29, 39, 40, 44, 51, 52, <i>et al.</i> ; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (Complaint ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Adam Fein, <i>Five takeaways from the big three PBMs’ 2022 formulary exclusions</i> (Jan. 19, 2022); Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, <i>Priced Out of a Lifesaving Drug: Getting Answers on the Rising</i>	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				<i>Cost of Insulin</i> (Apr. 10, 2019).		
“Over the last three years . . . CVS Caremark has helped our clients save more than \$141 billion by blunting drug price inflation, prioritizing the use of effective, lower-cost drugs and reducing the member’s out-of-pocket spend.”	Apr. 11, 2019	Derica Rice, CVS Caremark, press release	Public statement/press release	<i>See, e.g.,</i> RAND Report; Senate Insulin Report at 41-46, 49-89; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (Complaint ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin” (Apr. 10, 2019).	Unknown at this time.	CVS
The Manufacturer Payments that the PBMs	Apr. 16 and 26, 2019;	Letters to Sens. Grassley and Wyden from	Senators Chuck Grassley	The amount the Manufacturers kick back to the PBMs is directly	Unknown at this time.	CVS, Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
receive are not correlated to rising insulin prices.	May 24, 2019; <i>et al.</i>	CVS (4/26/19, 5/24/19) and Cigna (4/16/19), <i>et al.</i>	and Ron Wyden	correlated to an increase in list prices. On average, a \$1 increase in Manufacturer Payments is associated with a \$1.17 increase in list price. <i>See, e.g., Neeraj Sood, et al., The Association Between Drug Rebates and List Prices</i> , USC Schaeffer Ctr. for Health Policy & Econ. (Feb. 11, 2020) <i>See also, e.g., Senate Insulin Report at 66; Balto Testimony.</i>		
The Manufacturers are solely responsible for list price increases.	Apr. 16 and 26, 2019; May 24, 2019; <i>et al.</i>	Letters to Sens. Grassley and Wyden from CVS (4/26/19, 5/24/19) and Cigna (4/16/19), <i>et al.</i>	Senators Chuck Grassley and Ron Wyden	The PBMs manipulate formularies, trade placement for kickbacks, mislabel rebates; the Manufacturers raise prices with an eye toward PBM preferences. <i>See, e.g., The Association Between Drug Rebates and List Prices</i> , USC Schaeffer Ctr. for Health Policy &	Unknown at this time.	CVS, Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Econ. (Feb. 11, 2020) <i>See also, e.g., Senate Insulin Report at 58, 65-66, 87; Balto Testimony; Adam Fein, Five takeaways from the big three PBMs' 2022 formulary exclusions</i> (Jan. 19, 2022); Shepherd, Fein, Percher, <i>supra</i> .		
The PBMs were solely to blame for insulin prices because of their demands for rebates in exchange for formulary placement.	Mar. 8, 2019	Manufacturer Defendants	Manufacturers' Letters to Sens. Grassley and Wyden; public statement.	Senate Insulin Report at 49-66.	Unknown at this time.	Eli Lilly, Novo Nordisk, Sanofi
Payors are not injured by Defendants' practices because "the list price is not what the payer is paying. They are paying the net price."	Apr. 10, 2019	Sumit Dutta, OptumRx	Public statement (Congressional testimony)	Shepherd; Fein; Percher, <i>supra</i> ; <i>See also, e.g., Senate Insulin Report; Broward County, Florida, Analysis of Broward County's Prescription Drug Coverage</i> , https://www.broward.org/Auditor/Reports/Reports/082019_Exh1_BCRxDrug_19-15.pdf .	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
Briefing materials prepared for Dave Ricks, Eli Lilly CEO, as a panelist at the 2017 Forbes Healthcare Summit included “Reactive Key Messages” on pricing that emphasized the significant research and development costs for insulin.	Nov. 29, 2017	Dave Ricks, Eli Lilly, at 2017 Forbes Healthcare Summit	Public statement	United States House of Representatives Committee on Oversight and Reform Drug Pricing Investigation Report, July 2021, at 3, 188-94; Senate Insulin Report; Natalie Shure, <i>The Insulin Racket</i> , AMERICAN PROSPECT (June 24, 2019).	Unknown at this time.	Eli Lilly
Research and development factors into the WAC for the at-issue drugs.	Mar. 29, 2019	Letter from Jeffrey Handwerker, Counsel, Arnold & Porter, on behalf of Sanofi, to Sens. Grassley and Wyden	Sens. Grassley and Wyden	Senate Insulin Report at 17 <i>et seq.</i> ; United States House of Representatives Committee on Oversight and Reform Drug Pricing Investigation Report, July 2021, at 3, 188-94; Natalie Shure, <i>The Insulin Racket</i> , AMERICAN PROSPECT (June 24, 2019).	Unknown at this time.	Sanofi
Executives from Novo Nordisk also falsely represented that research and development costs were key factors driving	Throughout the relevant period	Various	Public statements	United States House of Representatives Committee on Oversight and Reform Drug Pricing	Unknown at this time.	Novo Nordisk

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
the at-issue price increase.				Investigation Report, July 2021, at 3, 188-94; Senate Insulin Report.		
CVS Health administers benefit plans and designs formularies to reduce costs for its clients, make generics available, where possible, and improve the safety, effectiveness, and convenience of prescription drugs.	Dec. 31, 2010; Dec. 31, 2011; Dec. 31, 2012; Dec. 31, 2013; Dec. 31, 2014; Dec. 31, 2015; Dec. 31, 2016; Dec. 31, 2017; Dec. 31, 2018; Dec. 31, 2019; Dec. 31, 2020; Dec. 31, 2021; Dec. 31, 2022 Dec. 31, 2023	CVS Health Annual Reports (Form 10-K) (FY 2010-2023)	S.E.C.; public statement	<i>See, e.g.,</i> RAND Report; Senate Insulin Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (C ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019).	Unknown at this time.	CVS
In making formulary recommendations, Express Scripts’ Pharmacy & Therapeutics Committee considers the drug’s	Dec. 31, 2010; Dec. 31, 2011; Dec. 31, 2012; Dec. 31, 2013;	Express Scripts Holdings Annual Reports (Form 10-K)	S.E.C.; public statement	Balto Testimony	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
safety and efficacy, without any information on or consideration of the cost of the drug, including any discount or rebate arrangement that Express Scripts negotiates with the Manufacturer, and that Express Scripts fully complies with the P&T Committee's clinical recommendations regarding drugs that must be included or excluded from the formulary.	Dec. 31, 2014; Dec. 31, 2015; Dec. 31, 2016; Dec. 31, 2017.	(FY 2010-2017)				
OptumRx's rebate contracting and formulary management help clients achieve a low-cost, high-quality pharmacy benefit. OptumRx promotes lower costs by using formulary programs to produce better unit costs, encouraging patients to use drugs that offer improved value.	Dec. 31, 2010; Dec. 31, 2011; Dec. 31, 2012; Dec. 31, 2013; Dec. 31, 2014; Dec. 31, 2015; Dec. 31, 2016; Dec. 31, 2017; Dec. 31, 2018; Dec. 31, 2019.	UnitedHealth Group's Annual Reports (Form 10-K) (FY 2010-2019)	S.E.C.; public statement	<i>See, e.g., The RAND Report; Senate Insulin Report; Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Industry Shepherd; Fein; Percher, supra; Written testimony</i>	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
CVS Caremark was focused on diabetes to “help us add value for our PBM clients and improve the health of plan members . . .”	May 11, 2010	Press release	Media, reported in Chain Drug Review, https://www.chaindrugreview.com/cvs-expands-extracare-for-diabetes-products/ , among other sources	<i>See, e.g.,</i> RAND Report; Senate Insulin Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending</i> Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin	Unknown at this time.	CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				(Apr. 10, 2019); Balto Testimony.		
“CVS is working to develop programs to hold down [diabetes] costs.”	June 22, 2010	Andrew Sussman, Chief Medical Officer, CVS Caremark	Public statement (CBS News)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	CVS
CVS Caremark representation that formulary decisions related to insulin products were “one way the company helps manage costs for	Nov. 8, 2012	Public statement (published in Wall Street Journal)	Public statement	<i>See, e.g.,</i> The RAND Report; Senate Insulin Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ;	Unknown at this time.	CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
clients.”				<i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); <i>Industry Shepherd</i> ; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Express Scripts, discussing a program involving insulin, “disputed the idea that Express Scripts contributes to rising drug costs.”	May 8, 2017	Timothy Wentworth, CEO of Express Scripts	Public statement (published in New York Times)	<i>See, e.g., RAND Report; Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Express Scripts “helps our clients and diabetes patients prevail over cost and care challenges created by [diabetes].”	Aug. 31, 2016	Glen Stettin, Senior Vice President and Chief Innovation Officer, Express Scripts	Public statement (published in St. Louis Business Journal)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce,	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				“Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Express Scripts “broaden[s] insulin options for patients and bend[s] down the cost curve of what is currently the costliest class of traditional prescription drugs.”	Aug. 23, 2016	Glen Stettin, Senior Vice President and Chief Innovation Officer, Express Scripts	Public statement (press release)	See, e.g., RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	Express Scripts
For “insulin products . . . [OptumRx] negotiate[s] with brand manufacturers	Apr. 2019	Dr. Sumit Dutta, SVP and Chief	U.S. Congress;	See, e.g., RAND Report; <i>Drug Pricing</i>	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
to obtain significant discounts off list prices on behalf of our customers.”		Medical Officer of OptumRx, Congressional testimony	public statement.	<i>Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, supra; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.</i>		
OptumRx “has been at the forefront of efforts to improve access to affordable insulin and provide comprehensive care to patients with diabetes.”	May 10, 2023	Heather Cianfrocco, CEO, OptumRx	Public statement/ written testimony to U.S. Senate Committee on Health, Education, Labor, and Pensions	<i>See, e.g., RAND Report; Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi</i>	Unknown at this time.	Optum Rx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
“At Express Scripts we’re dedicated to keeping our promises to patients and clients . . . This commitment defines our culture, and all our collective efforts are focused on our mission to make the use of prescription drugs safer and more affordable.”	2015-24	Express Scripts Code of Conduct	Public statement (published on Express Scripts website)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm.	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
“At Express Scripts we negotiate lower drug prices with drug companies on behalf of our clients, generating savings that are returned to patients in the form of lower premiums and reduced out-of-pocket costs.”	April 2019	Amy Bricker, President, Express Scripts, Congressional Testimony	U.S. Congress; public statement	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
“Express Scripts remains committed to . . . patients with diabetes and creating affordable access to their medications.”	April 2019	Amy Bricker, President, Express scripts, Congressional Testimony	U.S. Congress; public statement	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	Express Scripts
“We reduce the costs of prescription drugs [and] we are leading the way to ensure that those discounts directly benefit consumers. . . . OptumRx’s pharmacy care services business is achieving better health outcomes for patients,	Apr. 9, 2019	John Prince, CEO, OptumRx	U.S. Senate Finance Committee (and published in Senate Insulin Report)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
lowering costs for the system, and improving the healthcare experience for consumers. . . . OptumRx negotiates better prices with drug manufacturers for our customers and for consumers.”				(COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Statement by CVS Caremark that the goal of its pharmacy benefit plans is to ensure “that the cost of a drug is aligned with the value it delivers in terms of patient outcomes”	Apr. 5, 2018	CVS Health, 2017 Drug Trend Report	Public statement	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ;	Unknown at this time.	CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
“Drugmakers set prices, and we exist to bring those prices down.”	Feb. 2017	Tim Wentworth, CEO, Express Scripts	Shareholders (earnings call); public.	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				(Apr. 10, 2019); Balto Testimony.		
“Any suggestion that PBMs are causing prices to rise is simply erroneous.”	Feb. 15, 2017	Larry Merlo, CVS Caremark	Shareholders (earnings call); public.	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin” (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	CVS
PBMs play no role in rising drug prices, and work to “negotiate with drug companies to get the prices down.”	Feb. 7, 2017	Tim Wentworth, Express Scripts	Public (via CBS News)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Rebates do not cause increases in list prices.	Apr. 10, 2019	Sumit Dutta, Chief Medical Officer, OptumRx	House Energy and Commerce Subcommittee on Oversight and Investigations (testimony)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27));	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
“I have no idea why the prices [for insulin] are so high, none of it is the fault of rebates.”	Apr. 10, 2019	Amy Bricker, Express Scripts	House Energy and Commerce Subcommittee on Oversight and Investigations (testimony)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
PBMs “exist to help solve the challenge[]” of rising drug prices, including insulin, by “negotiating with large pharmaceutical manufacturers to lower the cost of drugs for employers, health plans, federal and state governments, and most importantly, patients.”	May 10, 2023	Adam Kautzner, President, Express Scripts	U.S. Senate Committee on Health, Education, Labor, and Pensions	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	Express Scripts
“We want our clients to fully understand our pricing structure Every day we strive to show our commitment to our clients, and one	Sept. 13, 2011	Ed Feaver, President, OptumRx	Public statement (press release)	Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up</i>	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
element of that commitment is to be open and honest about our pricing structure.”				<i>Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto Testimony.		
Express Scripts is “absolutely transparent” about the Manufacturer Payments it receives and payors “know exactly how the dollars flow” with respect to these Manufacturer Payments.	Feb 7, 2017	Tim Wentworth, CEO, Express Scripts	Public statement (CBS News)	Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto Testimony.	Unknown at this time.	Express Scripts
“[A]s it pertains to transparency overall, we at CVS Caremark are very supportive. We provide full visibility to our clients of all our contracts and the discounts that we negotiate on their behalf. . . . And transparency—today we report and fully disclose not only to our clients, but to CMS [Medicare].”	2019	Derica Rice, Executive Vice President, CVS Caremark	Senate Finance Committee (testimony)	<i>See, e.g.,</i> Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto Testimony.	Unknown at this time.	CVS
“[W]e are really a strong proponent for transparency for those who pay for health care. So the patient should know exactly what they are going to pay. Our plan sponsors need to know exactly what is in their contract.”	2019	Steve Miller, Cigna	Senate Finance Committee (testimony)	<i>See, e.g.,</i> Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Testimony.		
“[I]f our discounts were publicly available, it would hurt our ability to negotiate effectively. Our discounts are transparent to our clients.”	2019	John Prince, OptumRx	Senate Finance Committee (testimony)	<i>See, e.g.,</i> Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up Drug Costs</i> , Competition Policy Int’l (May 31, 2022); Balto Testimony.	Unknown at this time.	OptumRx
“The rebate system is 100 percent transparent to the plan sponsors and the customers that we service. To the people that hire us, employers of America, the government, health plans, what we negotiate for them is transparent to them.”	April 10, 2019	Amy Bricker, Senior Vice President, Express Scripts	House Energy and Commerce Subcommittee on Oversight and Investigations (testimony)	<i>See, e.g.,</i> Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up Drug Costs</i> , Competition Policy Int’l (May 31, 2022); Balto Testimony.	Unknown at this time.	Express Scripts
Optum Health, Optum Insight, and Optum Rx “improve overall health system performance by . . . reducing costs and improving consumer and provider experience[.]”	Dec. 31, 2022	UnitedHealth Group Form 10-K	S.E.C.; public statement	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
The PBMs work to secure the lowest possible net costs for the at-issue drugs by soliciting competing rebate offers.	Apr. 26, 2019	Letter from CVS Health Corp. to Sens. Grassley and Wyden	Sens. Grassley and Wyden; public statement	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug:	Unknown at this time.	CVS Health

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
The PBMs work to secure the lowest possible net costs for the at-issue drugs by soliciting competing rebate offers.	Dec. 7, 2020	Letter from Cigna to Sens. Grassley and Wyden	Sens. Grassley and Wyden; public statement	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	Express Scripts

22. statement, and if so, how, and the Defendant(s) that made the statement:

23. In the form of the table below, describe any omissions that a Defendant allegedly made that forms the basis of the allegations in Your lawsuit, of which You are currently aware, including the approximate date, any statement to which the omission relates, the reason why You believe a Defendant should have disclosed the omission, and the Defendant(s) that made the omission:

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The list prices for the at-issue drugs are artificially inflated with kickbacks (“fees,” “discounts,” “credits,” etc.) that are mislabeled rebates that should be passed through to payors.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere that all rebates are passed through to payors; price inflation is not due to rebates; payments in question are actually “discounts,” “credits,” “fees”; PBMs honor price transparency; all rebates are subject to audit; payors are not injured by skyrocketing prices; payors are to blame for skyrocketing prices; and the pricing for the at-issue drugs is transparent.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants.

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The Manufacturers engage in shadow pricing.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere reflecting that pricing is transparent; pricing is competitive pricing; Defendants work to keep prices low for clients.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	Eli Lilly, Novo Nordisk, Sanofi.

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The PBMs grant Manufacturers preferred formulary coverage in exchange for rebates.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere reflecting that PBMs design formularies to promote health, cost-effectiveness/affordability, and access to diabetes and other medications.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
Express Scripts, CVS, and OptumRx use formulary exclusions and threats of formulary exclusions and preferred formulary status to extract greater rebates and keep list prices high.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere regarding formulary management, physician/panel formulary review, resulting cost savings to clients and patients, and access to medications.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	Express Scripts, CVS, OptumRx.

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The Manufacturers adjust prices in keeping with the PBMs' interests.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere reflecting that pricing is transparent; pricing is competitive pricing; Defendants work to keep prices low for clients.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The rising prices of insulins and GLP-1s hurt payors.	Throughout the relevant period	Rising prices of these medications hurt only patients, particularly uninsured and high-deductible patients; 100% of rebates are passed through to payors; payors are to blame for rising prices.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The PBMs use rebate aggregators to obscure the total rebates paid to the PBMs.	Throughout relevant period	Various representations above, cited in Complaint, and elsewhere that all rebates are passed through to payors; price inflation is not due to rebates; payments in question are actually “discounts,” “credits,” “fees”; PBMs honor price transparency; all rebates are subject to audit.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	Express Scripts, CVS, OptumRx.

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
Eli Lilly's generic version of Humalog, "Insulin Lispro," would be excluded from PBM formularies.	March 2019	Eli Lilly would produce Insulin Lispro and make it available at half the price of Humalog, with the goal of making insulins more affordable.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	Eli Lilly, CVS, OptumRx, Express Scripts

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The Manufacturers increase rebate offers, leading to higher list prices, in order to block competitors from the PBMs' formularies.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere that rebates are not connected to rising list prices; pricing is transparent; formularies are designed to optimize health benefits and cost-effectiveness.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants

VIII. TIMING OF AWARENESS

24. Identify when and how You first learned or discovered that the prices for the At-Issue Products were allegedly artificially inflated, false, fraudulent, misleading, or deceptive:

Objection. Plaintiff objects that this question calls for information protected by the attorney client privilege. Subject to and without waiving this objection Plaintiff responds: To the best of its recollection, on or about July 2024 Plaintiff learned or discovered that the prices for the At-Issue Products were artificially inflated, false, fraudulent, misleading or deceptive through Plaintiff Representatives.

25. Identify the earliest date on which You began investigating the pricing of Defendants' At-Issue Products for the purpose of bringing the present action:

To the best of its recollection, on or about July 2024 Plaintiff began investigating the pricing of Defendants' At-Issue Products for the purpose of bringing the present action.

26. Identify when You first learned or discovered that Defendants' statements about the prices for the At-Issue Products were allegedly false, fraudulent, misleading, or deceptive:

To the best of its recollection, on or about July 2024 Plaintiff learned or discovered that Defendants' statements about the prices for the At-Issue Products were false, fraudulent, misleading or deceptive.

27. Describe how You first learned or discovered that Defendants' statements about the prices for the At-Issue Products were allegedly false, fraudulent, misleading, or deceptive:

Objection. Plaintiff objects that this question calls for information protected by the attorney client privilege. Subject to and without waiving this objection Plaintiff responds: Through conversations with Plaintiff Representatives.

28. Identify when and how You learned of or discovered any other lawsuit filed against any Defendant related to insulin pricing, including *In re Insulin Pricing* (D.N.J., 2:17-cv-00699), *MSP LLC* (D.N.J., 2:18-cv-02211), *Minnesota* (D.N.J., 2:18-cv-14999), and *In re Direct Purchaser Insulin Pricing Litigation* (D.N.J., 3:20-cv-03426):

Objection. Plaintiff objects that this question calls for information protected by the attorney client privilege. Subject to and without waiving this objection Plaintiff responds: To the best of its recollection on or about July 2024 Plaintiff learned of other lawsuits filed against any Defendant related to insulin pricing through Plaintiff Representatives.

29. Identify when and how You learned of or discovered any state, or federal investigation related to insulin pricing:

Objection. Plaintiff objects that this question calls for information protected by the attorney client privilege. Subject to and without waiving this objection Plaintiff responds: To the best of its recollection, on or about July 2024 Plaintiff learned of state and/or federal investigations related to insulin pricing through Plaintiff Representatives.

IX. SELECTION OF PRESCRIPTION DRUG COVERAGE

30. In the form of the table below, identify any third-party services, advisors, consultants, or contractors used by You to provide consulting, research, analysis, accounting, financial advice, solicitation, selection, development, or other advice related to Your Health Plan, selecting or soliciting PBM services, or Prescription Drug Coverage for At-Issue Products during the Time Period, the approximate dates You used the third-party services, advisors, consultants, or contractors, a description of the services that entity provided You, and the principal point of contact at the entity who is or was responsible for overseeing performance of the contract:

Third-Party Advisor (Advisor Name and Employer)	Approximate Dates	Description of Services	Point of Contact
Bolton		Plan Administrator	

31. For each third-party service, advisor, consultant, or contractor You identified in Question No. 29, in the form of the table below or through the production of documents, identify whether You received any presentations, reports, analyses, or memoranda related to Health Plan or Prescription Drug Coverage benefits designed for At-Issue Products, and produce those materials:

Unknown at this time but Plaintiff reserves the right to supplement this response.

Third-Party Advisor	Received Presentations, Reports, Analyses, Memoranda (Yes/No)

32. Did You or anyone acting on Your behalf conduct a request for proposal (“RFP”) or similar process to solicit offers from or to otherwise identify PBMs to administer Prescription Drug Coverage? ____ Yes ____ No

Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, in the form of the table below, identify each RFP or other solicitation You made during the Time Period, any third-party advisor that assisted with the RFP or solicitation, the PBMs You sent the RFP or solicitation to, and produce the RFP responses:

RFP or Solicitation	Third-Party Advisor	Date	PBMs Solicited

33. Are Your Health Plan expenditures related to pharmaceuticals audited, either internally or by an external auditor? ____ Yes ____ No

Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, in the form of the table below, identify each audit and produce the audit:

Audit	Person or Entity conducting the Audit	Date	Purpose of the audit

X. MEMBERSHIP IN OTHER ENTITIES

34. In the form of the table below, identify any organizations that You are a part of that share information regarding at-issue insulins, pharmaceutical pricing, Rebates, PBM or drug pricing reform or legislation, including, but not limited to, the National Association of Counties, MMCAP, or any other group purchasing organization, and identify any of Your employees who are involved in that organization:

Organization	Dates of Membership	Your Involved Employees
N/A		

XI. DIRECT PURCHASING

35. Have You purchased At-Issue Products directly from pharmaceutical manufacturers, wholesalers, mail order pharmacies, and/or retail sellers? ____ Yes ____ No

If yes, in the table below, identify each At-Issue Product You allege You purchased directly, the specific years You made the direct purchase, the entity that directly distributed the At-Issue Product(s) to You, the total quantity of At-Issue Products You purchased, and the total amount You paid:

At-Issue Product	Year	Direct Seller	Total Quantity	Total Amount Paid
N/A				

XII. DAMAGES

36. For each Defendant identified in Question No. 4, in the form of the table below, state how You claim You have been damaged by that Defendant's alleged conduct. This request is not designed to require an expert evaluation:

Defendant	Basis
All Defendants	<p>Plaintiff has incurred and continues to incur direct and indirect monetary costs and harms as a result of Defendants' misconduct.</p> <p>The direct monetary costs and harms include <i>inter alia</i> (i) the increased costs Plaintiff has paid and continues to pay for the artificially inflated prices for the at-issue drugs as a result of Defendants' misconduct, (ii) increased fees Plaintiff has paid and continues to pay PBM Defendants for their services as a result of all Defendants' misconduct, and (iii) the failure of the PBM Defendants to pass through the full amount of rebates they claim to provide to Plaintiff as a result of all Defendants' misconduct.</p> <p>The indirect monetary costs and harm include <i>inter alia</i> lost opportunity costs, reduced bargaining power, increased burden to employees and staff, and the inability to allocate resources to other programs and services provided by Plaintiff in its capacity as a government entity.</p> <p>Plaintiff also incorporates by reference the damages set forth in its complaint and in its initial disclosures.</p>

	Both direct and indirect monetary costs and harms will be identified, specified, and quantified at trial, including based on discovery provided by Defendants, publicly available information, and fact and expert testimony.
--	---

37. For each Defendant identified in Question No. 4, in the form of the table below, identify to the best of Your knowledge the date when You allege that You were first injured as a result of that particular Defendant's alleged conduct. This request is not designed to require an expert evaluation:

Defendant	Date
For all Defendants	<p>Because of Defendants' misconduct, Plaintiff cannot pinpoint a specific month and year when it first began to incur direct and indirect monetary costs described above in response to Question 35. As set forth in Plaintiff's complaint and in response to Questions 23-28 above, each Defendant failed to disclose material facts sufficient for Plaintiff to identify Plaintiff's injury, its cause, and other operative facts supporting its claims.</p> <p>However, as set forth in response to Questions 23-28, Plaintiff recently became aware of information regarding Defendants' misconduct. Based on a reasonable investigation and information and belief, the exact date Plaintiff first became injured as a result of Defendants' misconduct is the date of their first interaction(s) wherein Defendants inflated prices.</p>

38. Are You seeking any monetary damages? x Yes No

If yes, summarize the categories of damages or monetary relief that You allege:

Plaintiff seeks past and future damages and monetary relief. As set forth in response to Question 35, Plaintiff seeks direct and indirect monetary costs it has paid and will continue to pay as a result of Defendants' misconduct. Plaintiff also seeks statutory damages and relief that are monetary in nature pursuant to its RICO, Antitrust, and state claims. Plaintiff also seeks injunctive relief to ensure that prices for at issue drugs remain appropriately priced prospectively.

INITIAL DOCUMENT REQUESTS

Please produce the following documents for the Time Period:

1. Each RFP seeking PBM services, including all amendments, riders, schedules, supplements, instructions, or other addenda that You issued during the Time Period.
2. Documents, including internal summaries, analyses, and presentations, reflecting Your reasons for selecting or not selecting a PBM prescription drug benefit plan for each year, including bids, communications, RFPs, procurement rules, guidance documents, and related documents, and documents relating to negotiation for Rebates for Your employee plan(s) or for Medicaid.
3. Each contract, including amendments, riders, schedules, supplements, or other addenda that You entered into with a PBM, health insurer, third-party administrator, or any other entity through which You obtained price concessions during the Time Period (e.g., MMCAP), or that otherwise was in effect during the Time Period.
4. Documents sufficient to identify the formularies for Your Health Plans during the Time Period.
5. For each benefit year for which You are seeking relief, documents relating to Your Health Plans, including documents sufficient to show: (1) the annual deductible(s), including separate deductible amounts or requirements for use of in-network versus out-of-network pharmacies, and any separate deductible amounts or requirements on individual versus family expenditures, (2) the copayment or coinsurance rate for each pharmaceutical tier, (3) the annual Out-of-Pocket Maximums, (4) the summary plan description, and (5) summaries of benefits and coverage associated with each of Your Health Plans during the time period.
6. Documents received by You that related to representations made by PBMs about their services or made by pharmaceutical manufacturers about their list prices.
7. Contracts with third-party advisors or auditors in effect during the Time Period that relate to prescription drug benefits, as well as any presentations, reports, analyses, or memoranda relating to prescription drug benefits Plaintiffs chose or did not choose.

CERTIFICATION

I declare under penalty of perjury that all of the information provided in this PFS is complete, true, and correct to the best of my knowledge and information, and that I have provided all of the requested documents that are reasonably accessible to me and/or my attorneys, to the best of my knowledge.

Zulieka Hensy
Signature

Dr. Zulieka Hensy
Name (Printed)

2/19/25
Date

Asst. Supt of Admin Services
Title

QUESTIONS

I. CASE INFORMATION

1. Plaintiff: Stockbridge Community Schools
2. Case name and caption number: In Re: Insulin Pricing Litigation Plaintiff v. Eli Lilly and Company et al.; Case No.: 2:24-cv-11216
3. Name, firm, and e-mail of principal attorney(s) representing You: Frantz Law Group, APLC, wshinoff@frantzlawgroup.com
4. Defendants: Eli Lilly and Company, Sanofi-Aventus U.S. LLC, Novo Nordisk Inc., CVS Health Corporation, CVS Pharmacy, Inc. Caremark Rx LLC, Caremark LLC, CaremarkPCS Health, LLC, EverNorth Health, Inc., Express Scripts Inc., Express Scripts Administrators, LLC, Medco Health Solutions, Inc., ESI Mail Pharmacy Services, Inc., Express Scripts Pharmacy Inc., UnitedHealth Group, Inc., United Healthcare Services, Inc., UnitedHealthcare Insurance Co., Optum Inc., OptumRx, Inc. and OptumInsight, Inc.

II. BENEFICIARIES

5. In the table below, provide the total number of individuals enrolled in Your Health Plan, including primary and dependent beneficiaries, for each year of the Time Period:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Year	Number of Beneficiaries
2011	
2012	
2013	
2014	
2015	
2016	228
2017	224
2018	217
2019	213
2020	209
2021	213
2022	235

6. Provide the total number of individuals who used Your Health Plan to purchase or use At-Issue Products during each year of the Time Period:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Year	Number of Purchasers/Users of At-Issue Products
2011	
2012	
2013	
2014	
2015	
2016	1
2017	2
2018	4
2019	5
2020	3
2021	3
2022	3

III. PERSONS OR ENTITIES WITH RELEVANT KNOWLEDGE

7. In the form of the table below, identify the name, title, and dates of employment of Your current and former employees, representatives, or agents who had any responsibility over the design or administration of Your Health Plan or Prescription Drug Coverage during the Time Period, including responsibility over the decision to enter into agreements governing Prescription Drug Coverage, Rebates, Your Health Plan, and formularies:

Name	Title	Dates of Employment or Contract	Area(s) of Responsibility

8. To the extent not included in response to Question No. 7 above, in the form of the table below, identify by name, title, and dates of employment Your current and former employees or representatives with knowledge regarding the allegations in Your Complaint:

Name	Title	Dates of Employment	Area(s) of Responsibility

9. In the form of the table below, identify by name any department, agency, investigative unit, entity, or other program with responsibility over functions related to the allegations in Your Complaint. Summarize each of those entities' area of responsibility:

Entity Name	Area of Responsibility

IV. AT-ISSUE PRODUCTS

10. Identify every insulin or other pharmaceutical that You allege is relevant to any claim for damages or other relief You seek in this case (the “At-Issue Products”):¹

Humulin R, Humulin R 500, Novolin R, Humulin N, Humulin 70/30, Novolin N, Novolin 70/30, Humalog, Novolog, Apidra, Humalog 50/50, Humalog 75/25, Novolog 70/30, Lantus, Levemir, Basaglar (Kwikpen), Toujeo (Solostar), Tresiba, Trulicity (Dulaglutide), Mounjaro (Tirzepatide/GIP), Victoza (Liraglutide), Xultophy (insulin degludec/liraglutide), Ozempic (Semaglutide), Rybelsus (semaglutide tablets), Adylxin (lixisenatide), Soliqua (insulin glargine/lixisenatide)

11. In the form of the table below or through the production of documents, for each At-Issue Product, provide the total amount of money that You spent on the At-Issue Product for members enrolled in Your Health Plan for each year during the Time Period, and the total Rebates received by You:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

¹ In seeking this information, Defendants do not concede that any pharmaceuticals identified by You are relevant.

At-Issue Product	Year	Total Number of Scripts	Total Spent by You	Total Rebates Received
Humalog	2016	1	\$1,008	\$0
Humalog	2017	1	\$2,536.25	\$0
Lantus	2017	9	\$12,506.46	\$0
Basaglar	2018	1	\$1,656.29	\$0
Apidra	2018	1	\$536.06	\$0
Tresiba	2018	1	\$452.95	\$0
Lantus	2018	7	\$6,314.96	\$0
Apidra	2019	1	\$1,732.68	\$0
Lantus	2019	8	\$4,963.29	\$0
Novolog	2019	1	\$1,767.17	\$0
Tresiba	2019	2	\$925.42	\$0
Trulicity	2019	4	\$2,917.44	\$0
Victoza	2019	6	\$5,161.32	\$0
Lantus	2020	6	\$2,265.59	\$0
Novolog	2020	9	\$9,612.47	\$0
Trulicity	2020	11	\$8,465.93	\$0
Lantus	2021	5	\$1,841.34	\$0
Novolog	2021	8	\$9,213.72	\$0
Trulicity	2021	11	\$9,015.93	\$0
Lantus	2022	1	\$374.39	\$0
Novolog	2022	2	\$3,534.34	\$0
Ozempic	2022	1	\$870.31	\$0
Trulicity	2022	7	\$6,051.29	\$0

V. YOUR HEALTH PLANS

12. In the form of the table below, for each Health Plan that You offered that included Prescription Drug Coverage during the Time Period, identify the plan identification

number, name, or other plan identifier and the starting and ending dates for each plan year during the Time Period:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Health Plan Identifier	Start Date	End Date

13. In the form of the table below, list all PBMs or other entities with whom You have contracted to administer Prescription Drug Coverage for every Health Plan identified in response to Question No. 12 for each plan year during the Time Period:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Health Plan Identifier	Plan Year	PBM or Other Entity

14. Identify all insurers or third-party administrators with whom You have contracted relating to the Health Plans identified in response to Question No. 12:

VI. **REBATES AND FEES**

15. In the form of the table below, identify each contract You have or had with a PBM during the Time Period, including the party with which You contracted, and the year. Include in Your answer any addendums or other agreements You entered pursuant to an existing master agreement. If a contract was entered into before the Time Period began but did not expire until after the Time Period began, identify that contract as well:

After diligent search and reasonable inquiry, Plaintiff is not in the possession, custody, or control of the responsive information and/or documents. Plaintiff believes Defendants are in possession of this information and/or documents. Plaintiff reserves the right to supplement this response.

Contract	Contracting Entity	Year(s)

16. Have You ever used preventative drug lists, critical drug affordability programs, or any other program to lower the out-of-pocket costs of the At-Issue Products for Your members?

____ Yes X No

Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, in the form of the table below, identify each such Health Plan where You implemented such a program, the program, the year the program was implemented, and the applicable At-Issue Products:

Health Plan	Program	Year	At-Issue Product

17. Have You ever passed Rebates received from a PBM through to Your members at the point of sale for any of the At-Issue Products? ____ Yes X No Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, in the form of the table below, identify each such Health Plan where You passed on Rebates, the years You passed on Rebates, the At-Issue Products for which You passed on Rebates, and the percentage of Rebates that You passed on to members at the point of sale:

Health Plan	Year Passed on Rebate	At-Issue Product	Percentage of Rebate Passed on

18. Other than passing Rebates through to Your members at the point of sale, describe the ways in which You use Rebates and Administrative Fees received from PBMs for At-Issue Products: N/A

Unknown at this time but Plaintiff reserves the right to supplement this response.

19. In any contract identified in response to Question No. 15, did any other PBM or any other contracting entity submit bids/proposals? ____ Yes X No

Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, identify any entity submitting competing bids/proposals, and produce the competing bids:

20. During the relevant time period, did You contract with, or use master contracts from, any other entities (e.g., MMCAP) for rebates or other price concessions related to purchasing pharmaceutical products? _____ Yes X No

If yes, in the form of the table below, identify each such contract, the contracting entity, the year, and the percentage of or other determinant of the Rebates the contracting entity agreed to pass through to You:

Contract	Contracting Entity	Year	Percentage of Rebates

VII. MISREPRESENTATIONS AND OMISSIONS

21. In the form of the table below, identify every specific misrepresentation that a Defendant allegedly made that forms the basis of the allegations in Your lawsuit, of which You are currently aware, including the approximate date, the source, who received the statement, the reason why You believe the statement was false, whether or not You relied on the statement, and if so, how, and the Defendant(s) that made the statement:

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
False list prices for each of the at-issue drugs	Throughout the relevant period	All public compendia (including Medi-Span, First DataBank, Redbook, etc.)	All payors, including the Plaintiff.	<i>The Astronomical Price of Insulin Hurts Am. Families</i> , RAND (Jan. 6, 2021) (“RAND Report”); <i>Drug Pricing Investigation: Majority Staff Report</i> , Comm. on Oversight & Reform, U.S. H.R. (Dec. 2021) (“ <i>Drug Pricing Investigation</i> ”); Comm. on Energy & Commerce, Mem., <i>Hearing on “Priced Out of a Lifesaving Drug: Getting Answers on the</i>	Yes. The Plaintiff relied on the at-issue list prices each time it paid for an at-issue drug. Other payors, patients, and third parties also relied on the Manufacturers’ false prices.	Eli Lilly, Sanofi, Novo Nordisk

² The list of sources cited for each misrepresentation is not necessarily exhaustive. Where numerous sources support Plaintiff’s belief that a statement is false, Plaintiff has selected examples of authorities that support that belief. Other examples may be cited in Plaintiff’s Complaint or the entries in this chart addressing different misrepresentations, or may exist elsewhere.

³ No single source cited here was sufficient to put Plaintiff on notice of the Insulin Pricing Scheme described in the Complaint or the claims alleged therein. Plaintiff’s responses to the inquiries set forth in Section VIII (Timing of Awareness) describe when Plaintiff became aware of specific facts relating to the allegations in the Complaint.

⁴ Where named as Defendants, the PBM Defendants are identified by defendant group. “Express Scripts,” for example, refers to the Express Scripts family of defendants, including Evernorth Health, Inc.; Express Scripts, Inc.; Express Scripts Administrators, LLC; Medco Health Solutions, Inc.; ESI Mail Pharmacy Service, Inc.; and Express Scripts Pharmacy, Inc., and where Forms 10-K or other S.E.C. filings are at issue, occasionally non-defendant Cigna Corporation, which reports for these entities.

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				<p><i>Rising Cost of Insulin</i>” (Apr. 5, 2019) (“<i>Priced Out of a Lifesaving Drug</i>”); U.S. H.R., <i>Drug Pricing Investigation: Industry Spending on Buybacks, Dividends and Executive Compensation</i>, at 3 (July 2021) (“<i>Industry Spending Report</i>”); Natalie Shure, <i>The Insulin Racket</i>, AMERICAN PROSPECT (June 24, 2019); Joanna Shepherd, <i>Pharmacy Benefit Managers, Rebates, and Drug Prices: Conflicts of Interest in the Market for Prescription Drugs</i>, YALE L. & POLICY REV., Vol. 38 (Jan. 2019) (prices bloated with rebates and mislabeled rebates).”; Adam Fein, <i>Tex. Shows</i></p>		

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				<i>Us Where PBMs' Rebates Go</i> , DRUG CHANNELS (Aug. 9, 2022) (same); Eric Percher, <i>Trends in Profitability and Compensation of PBMs and PBM Contracting Entities</i> , Nephron Research (Sept. 18, 2023) (same). <i>See also</i> Senate Insulin Report at 41-46. 49-89; Broward Cnty., Fla., <i>Analysis of Broward Cnty.'s Prescription Drug Coverage</i> (Aug. 2019).		
False list prices as reflected in invoices Express Scripts and CVS issued to the Plaintiff.	Dates reflected on invoices, including, but not limited to, Other invoices PBM issued to the Plaintiff are no longer in its possession custody or control.	Routine invoices.	The Plaintiff.	See sources cited above.	Yes. The Plaintiff relied on the false invoiced price each time it paid for an at-issue drug.	All Defendants .

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
Manufacturer Payments are “fees,” “credits,” “discounts,” and other categories of payment when they are, in fact, rebates.	Throughout the relevant period.	Routine invoices and other payors for the at-issue medications	The Plaintiff.	Shepherd, <i>supra</i> (PBMs “designate as much as twenty-five or thirty percent of the negotiated rebates as fees to avoid sharing the rebates.”); Fein, <i>supra</i> (the PBMs retained between 9% and 21% of all Manufacturer Payments between 2016 and 2021); Percher, <i>supra</i> (PBM compensation from rebates and other kickbacks doubled between 2018 and 2022, from \$3.8 billion to \$7.6 billion. “This growth was fueled by increases in traditional administrative fees as well as the emergence of new data and PBM contracting entity fees.”); <i>See also</i> Broward County, Florida, Analysis, <i>supra</i> .	Yes. The Plaintiff and other payors rely on these representations.	OptumRx, Express Scripts, CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
Cigna provides “formulary management services” that “assist customers and physicians in choosing clinically-appropriate, cost-effective drugs and prioritize access, safety and affordability.”	Dec. 31, 2018 Dec. 31, 2019 Dec. 31, 2020 Dec. 31, 2021 Dec. 31, 2022 Dec. 31, 2023	Cigna Annual Report (Form 10-K) (FYE Dec. 31, 2018, Dec. 31, 2019, Dec. 31, 2020, Dec. 31, 2021, Dec. 31, 2022, Dec. 31, 2023.	S.E.C.; public statement	<i>See, e.g.,</i> RAND Report; Senate Insulin Report at 5-8, 29, 39, 40, 44, 51, 52, <i>et al.</i> ; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (Complaint ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (Complaint ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, <i>Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin</i> (Apr. 10, 2019); Adam Fein, <i>Five takeaways from the big three PBMs’ 2022 formulary</i>	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				<i>exclusions</i> (Jan. 19, 2022).		
“OptumRx works directly with pharmaceutical manufacturers to secure discounts that lower the overall cost of medications and create tailored formularies—or drug lists—to ensure people get the right medications. [<i>UnitedHealth Group</i>] then negotiate[s] with pharmacies to lower costs at the point of sale”	Dec. 31, 2020	UnitedHealth Group 2020 Sustainability Report	Public statement	<i>See, e.g.,</i> RAND Report; Senate Insulin Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (Complaint ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin” (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	United Health Group/ OptumRx
Express Scripts “saved [its] clients more than \$3 billion through the	January 11, 2016	Tim Wentworth, Express Scripts, at the	Public statement	<i>See, e.g.,</i> RAND Report; Senate Insulin Report at 5-8, 29, 39, 40,	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
Express Scripts National Preferred Formulary.”		34th annual JP Morgan Healthcare Conference		44, 51, 52, <i>et al.</i> ; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (Complaint ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Adam Fein, <i>Five takeaways from the big three PBMs’ 2022 formulary exclusions</i> (Jan. 19, 2022); Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, <i>Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin</i> (Apr. 10, 2019).		

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
“Over the last three years . . . CVS Caremark has helped our clients save more than \$141 billion by blunting drug price inflation, prioritizing the use of effective, lower-cost drugs and reducing the member’s out-of-pocket spend.”	Apr. 11, 2019	Derica Rice, CVS Caremark, press release	Public statement/press release	<i>See, e.g.,</i> RAND Report; Senate Insulin Report at 41-46, 49-89; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (Complaint ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin” (Apr. 10, 2019).	Unknown at this time.	CVS
The Manufacturer Payments that the PBMs receive are not correlated to rising insulin prices.	Apr. 16 and 26, 2019; May 24, 2019; <i>et al.</i>	Letters to Sens. Grassley and Wyden from CVS (4/26/19, 5/24/19) and	Senators Chuck Grassley and Ron Wyden	The amount the Manufacturers kick back to the PBMs is directly correlated to an increase in list prices. On average, a \$1	Unknown at this time.	CVS, Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
		Cigna (4/16/19), <i>et al.</i>		increase in Manufacturer Payments is associated with a \$1.17 increase in list price. <i>See, e.g., Neeraj Sood, et al., The Association Between Drug Rebates and List Prices</i> , USC Schaeffer Ctr. for Health Policy & Econ. (Feb. 11, 2020) <i>See also, e.g., Senate Insulin Report at 66; Balto Testimony.</i>		
The Manufacturers are solely responsible for list price increases.	Apr. 16 and 26, 2019; May 24, 2019; <i>et al.</i>	Letters to Sens. Grassley and Wyden from CVS (4/26/19, 5/24/19) and Cigna (4/16/19), <i>et al.</i>	Senators Chuck Grassley and Ron Wyden	The PBMs manipulate formularies, trade placement for kickbacks, mislabel rebates; the Manufacturers raise prices with an eye toward PBM preferences. <i>See, e.g., The Association Between Drug Rebates and List Prices</i> , USC Schaeffer Ctr. for Health Policy & Econ. (Feb. 11, 2020) <i>See also, e.g., Senate Insulin Report at 58, 65-</i>	Unknown at this time.	CVS, Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				66, 87; Balto Testimony; Adam Fein, <i>Five takeaways from the big three PBMs' 2022 formulary exclusions</i> (Jan. 19, 2022); Shepherd, Fein, Percher, <i>supra</i> .		
The PBMs were solely to blame for insulin prices because of their demands for rebates in exchange for formulary placement.	Mar. 8, 2019	Manufacturer Defendants	Manufacturers' Letters to Sens. Grassley and Wyden; public statement.	Senate Insulin Report at 49-66.	Unknown at this time.	Eli Lilly, Novo Nordisk, Sanofi
Payors are not injured by Defendants' practices because "the list price is not what the payer is paying. They are paying the net price."	Apr. 10, 2019	Sumit Dutta, OptumRx	Public statement (Congressional testimony)	Shepherd; Fein; Percher, <i>supra</i> ; <i>See also, e.g.,</i> Senate Insulin Report; Broward County, Florida, <i>Analysis of Broward County's Prescription Drug Coverage</i> , https://www.broward.org/Auditor/Reports/Reports/082019_Exh1_BCRxDrug_19-15.pdf .	Unknown at this time.	OptumRx
Briefing materials prepared for Dave Ricks, Eli Lilly CEO, as a panelist at the 2017 Forbes Healthcare Summit	Nov. 29, 2017	Dave Ricks, Eli Lilly, at 2017 Forbes Healthcare Summit	Public statement	United States House of Representatives Committee on Oversight and Reform Drug	Unknown at this time.	Eli Lilly

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
included “Reactive Key Messages” on pricing that emphasized the significant research and development costs for insulin.				Pricing Investigation Report, July 2021, at 3, 188-94; Senate Insulin Report; Natalie Shure, <i>The Insulin Racket</i> , AMERICAN PROSPECT (June 24, 2019).		
Research and development factors into the WAC for the at-issue drugs.	Mar. 29, 2019	Letter from Jeffrey Handwerker, Counsel, Arnold & Porter, on behalf of Sanofi, to Sens. Grassley and Wyden	Sens. Grassley and Wyden	Senate Insulin Report at 17 <i>et seq.</i> ; United States House of Representatives Committee on Oversight and Reform Drug Pricing Investigation Report, July 2021, at 3, 188-94; Natalie Shure, <i>The Insulin Racket</i> , AMERICAN PROSPECT (June 24, 2019).	Unknown at this time.	Sanofi
Executives from Novo Nordisk also falsely represented that research and development costs were key factors driving the at-issue price increase.	Throughout the relevant period	Various	Public statements	United States House of Representatives Committee on Oversight and Reform Drug Pricing Investigation Report, July 2021, at 3, 188-94; Senate Insulin Report.	Unknown at this time.	Novo Nordisk

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
CVS Health administers benefit plans and designs formularies to reduce costs for its clients, make generics available, where possible, and improve the safety, effectiveness, and convenience of prescription drugs.	Dec. 31, 2010; Dec. 31, 2011; Dec. 31, 2012; Dec. 31, 2013; Dec. 31, 2014; Dec. 31, 2015; Dec. 31, 2016; Dec. 31, 2017; Dec. 31, 2018; Dec. 31, 2019; Dec. 31, 2020; Dec. 31, 2021; Dec. 31, 2022 Dec. 31, 2023	CVS Health Annual Reports (Form 10-K) (FY 2010-2023)	S.E.C.; public statement	<i>See, e.g.,</i> RAND Report; Senate Insulin Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (C ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019).	Unknown at this time.	CVS
In making formulary recommendations, Express Scripts’ Pharmacy & Therapeutics Committee considers the drug’s safety and efficacy, without any information on or	Dec. 31, 2010; Dec. 31, 2011; Dec. 31, 2012; Dec. 31, 2013; Dec. 31, 2014; Dec. 31, 2015; Dec. 31,	Express Scripts Holdings Annual Reports (Form 10-K) (FY 2010-2017)	S.E.C.; public statement	Balto Testimony	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
consideration of the cost of the drug, including any discount or rebate arrangement that Express Scripts negotiates with the Manufacturer, and that Express Scripts fully complies with the P&T Committee's clinical recommendations regarding drugs that must be included or excluded from the formulary.	2016; Dec. 31, 2017.					
OptumRx's rebate contracting and formulary management help clients achieve a low-cost, high-quality pharmacy benefit. OptumRx promotes lower costs by using formulary programs to produce better unit costs, encouraging patients to use drugs that offer improved value.	Dec. 31, 2010; Dec. 31, 2011; Dec. 31, 2012; Dec. 31, 2013; Dec. 31, 2014; Dec. 31, 2015; Dec. 31, 2016; Dec. 31, 2017; Dec. 31, 2018; Dec. 31, 2019.	UnitedHealth Group's Annual Reports (Form 10-K) (FY 2010-2019)	S.E.C.; public statement	<i>See, e.g., The RAND Report; Senate Insulin Report; Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Industry Shepherd; Fein; Percher, supra;</i>	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
CVS Caremark was focused on diabetes to “help us add value for our PBM clients and improve the health of plan members . . .”	May 11, 2010	Press release	Media, reported in Chain Drug Review, https://www.chaindrugreview.com/cvs-expands-extracare-for-diabetes-products/ , among other sources	<i>See, e.g.,</i> RAND Report; Senate Insulin Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin	Unknown at this time.	CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				(Apr. 10, 2019); Balto Testimony.		
“CVS is working to develop programs to hold down [diabetes] costs.”	June 22, 2010	Andrew Sussman, Chief Medical Officer, CVS Caremark	Public statement (CBS News)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	CVS
CVS Caremark representation that formulary decisions related to insulin products were “one way the company helps manage costs for	Nov. 8, 2012	Public statement (published in Wall Street Journal)	Public statement	<i>See, e.g.,</i> The RAND Report; Senate Insulin Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending</i>	Unknown at this time.	CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
clients.”				Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); <i>Industry</i> Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Express Scripts, discussing a program involving insulin, “disputed the idea that Express Scripts contributes to rising drug costs.”	May 8, 2017	Timothy Wentworth, CEO of Express Scripts	Public statement (published in New York Times)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending</i> Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Express Scripts “helps our clients and diabetes patients prevail over cost and care challenges created by [diabetes].”	Aug. 31, 2016	Glen Stettin, Senior Vice President and Chief Innovation Officer, Express Scripts	Public statement (published in St. Louis Business Journal)	<i>See, e.g., RAND Report; Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, supra; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers</i>	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Express Scripts “broaden[s] insulin options for patients and bend[s] down the cost curve of what is currently the costliest class of traditional prescription drugs.”	Aug. 23, 2016	Glen Stettin, Senior Vice President and Chief Innovation Officer, Express Scripts	Public statement (press release)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	Express Scripts
For “insulin products . . . [OptumRx] negotiate[s] with brand manufacturers to obtain significant	Apr. 2019	Dr. Sumit Dutta, SVP and Chief Medical Officer of OptumRx,	U.S. Congress; public statement.	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending</i>	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
discounts off list prices on behalf of our customers.”		Congressional testimony		Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
OptumRx “has been at the forefront of efforts to improve access to affordable insulin and provide comprehensive care to patients with diabetes.”	May 10, 2023	Heather Cianfrocco, CEO, OptumRx	Public statement/ written testimony to U.S. Senate Committee on Health, Education, Labor, and Pensions	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending</i> Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27));	Unknown at this time.	Optum Rx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
“At Express Scripts we’re dedicated to keeping our promises to patients and clients . . . This commitment defines our culture, and all our collective efforts are focused on our mission to make the use of prescription drugs safer and more affordable.”	2015-24	Express Scripts Code of Conduct	Public statement (published on Express Scripts website)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
“At Express Scripts we negotiate lower drug prices with drug companies on behalf of our clients, generating savings that are returned to patients in the form of lower premiums and reduced out-of-pocket costs.”	April 2019	Amy Bricker, President, Express Scripts, Congressional Testimony	U.S. Congress; public statement	<i>See, e.g., RAND Report; Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, supra; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.</i>	Unknown at this time.	Express Scripts
“Express Scripts remains committed to . . . patients with diabetes and creating affordable access to their medications.”	April 2019	Amy Bricker, President, Express scripts, Congressional Testimony	U.S. Congress; public statement	<i>See, e.g., RAND Report; Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi</i>	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
“We reduce the costs of prescription drugs [and] we are leading the way to ensure that those discounts directly benefit consumers. . . . OptumRx’s pharmacy care services business is achieving better health outcomes for patients, lowering costs for the system, and improving the healthcare experience for	Apr. 9, 2019	John Prince, CEO, OptumRx	U.S. Senate Finance Committee (and published in Senate Insulin Report)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein;	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
consumers. . . . OptumRx negotiates better prices with drug manufacturers for our customers and for consumers.”				Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Statement by CVS Caremark that the goal of its pharmacy benefit plans is to ensure “that the cost of a drug is aligned with the value it delivers in terms of patient outcomes”	Apr. 5, 2018	CVS Health, 2017 Drug Trend Report	Public statement	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin	Unknown at this time.	CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				(Apr. 10, 2019); Balto Testimony.		
“Drugmakers set prices, and we exist to bring those prices down.”	Feb. 2017	Tim Wentworth, CEO, Express Scripts	Shareholders (earnings call); public.	See, e.g., RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	Express Scripts
“Any suggestion that PBMs are causing prices to rise is simply erroneous.”	Feb. 15, 2017	Larry Merlo, CVS Caremark	Shareholders (earnings call); public.	See, e.g., RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on	Unknown at this time.	CVS

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
PBMs play no role in rising drug prices, and work to “negotiate with drug companies to get the prices down.”	Feb. 7, 2017	Tim Wentworth, Express Scripts	Public (via CBS News)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ;	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
Rebates do not cause increases in list prices.	Apr. 10, 2019	Sumit Dutta, Chief Medical Officer, OptumRx	House Energy and Commerce Subcommittee on Oversight and Investigations (testimony)	<i>See, e.g., RAND Report; Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, supra; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019);</i>	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Balto Testimony.		
“I have no idea why the prices [for insulin] are so high, none of it is the fault of rebates.”	Apr. 10, 2019	Amy Bricker, Express Scripts	House Energy and Commerce Subcommittee on Oversight and Investigations (testimony)	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	Express Scripts
PBMs “exist to help solve the challenge[]” of rising drug prices, including insulin, by “negotiating with large pharmaceutical manufacturers to	May 10, 2023	Adam Kautzner, President, Express Scripts	U.S. Senate Committee on Health, Education, Labor, and Pensions	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
lower the cost of drugs for employers, health plans, federal and state governments, and most importantly, patients.”				Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
“We want our clients to fully understand our pricing structure Every day we strive to show our commitment to our clients, and one element of that commitment is to be open and honest about our pricing structure.”	Sept. 13, 2011	Ed Feaver, President, OptumRx	Public statement (press release)	Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up Drug Costs</i> , Competition Policy Int’l (May 31, 2022); Balto Testimony.	Unknown at this time.	OptumRx
Express Scripts is “absolutely transparent” about the Manufacturer Payments it receives and payors	Feb 7, 2017	Tim Wentworth, CEO, Express Scripts	Public statement (CBS News)	Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up</i>	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
“know exactly how the dollars flow” with respect to these Manufacturer Payments.				<i>Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto Testimony.		
“[A]s it pertains to transparency overall, we at CVS Caremark are very supportive. We provide full visibility to our clients of all our contracts and the discounts that we negotiate on their behalf. . . . And transparency—today we report and fully disclose not only to our clients, but to CMS [Medicare].”	2019	Derica Rice, Executive Vice President, CVS Caremark	Senate Finance Committee (testimony)	<i>See, e.g., Shepherd, Fein, Percher, supra; Senate Insulin Report; PBMs: The Middlemen Who Drive Up Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto Testimony.	Unknown at this time.	CVS
“[W]e are really a strong proponent for transparency for those who pay for health care. So the patient should know exactly what they are going to pay. Our plan sponsors need to know exactly what is in their contract.”	2019	Steve Miller, Cigna	Senate Finance Committee (testimony)	<i>See, e.g., Shepherd, Fein, Percher, supra; Senate Insulin Report; PBMs: The Middlemen Who Drive Up Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto Testimony.	Unknown at this time.	Express Scripts
“[I]f our discounts were publicly available, it would hurt our ability to negotiate effectively. Our discounts are	2019	John Prince, OptumRx	Senate Finance Committee (testimony)	<i>See, e.g., Shepherd, Fein, Percher, supra; Senate Insulin Report; PBMs: The Middlemen Who Drive Up</i>	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
transparent to our clients.”				<i>Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto Testimony.		
“The rebate system is 100 percent transparent to the plan sponsors and the customers that we service. To the people that hire us, employers of America, the government, health plans, what we negotiate for them is transparent to them.”	April 10, 2019	Amy Bricker, Senior Vice President, Express Scripts	House Energy and Commerce Subcommittee on Oversight and Investigations (testimony)	<i>See, e.g.,</i> Shepherd, Fein, Percher, <i>supra</i> ; Senate Insulin Report; <i>PBMs: The Middlemen Who Drive Up Drug Costs, Competition Policy Int’l</i> (May 31, 2022); Balto Testimony.	Unknown at this time.	Express Scripts
Optum Health, Optum Insight, and Optum Rx “improve overall health system performance by . . . reducing costs and improving consumer and provider experience[.]”	Dec. 31, 2022	UnitedHealth Group Form 10-K	S.E.C.; public statement	<i>See, e.g.,</i> RAND Report; <i>Drug Pricing Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and	Unknown at this time.	OptumRx

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant (s) ⁴
				Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.		
The PBMs work to secure the lowest possible net costs for the at-issue drugs by soliciting competing rebate offers.	Apr. 26, 2019	Letter from CVS Health Corp. to Sens. Grassley and Wyden	Sens. Grassley and Wyden; public statement	See, e.g., RAND Report; <i>Drug Pricing Investigation</i> ; <i>Priced Out of a Lifesaving Drug</i> ; <i>Industry Spending Report</i> ; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, <i>supra</i> ; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.	Unknown at this time.	CVS Health
The PBMs work to secure the lowest possible net costs	Dec. 7, 2020	Letter from Cigna to	Sens. Grassley	See, e.g., RAND Report; <i>Drug Pricing</i>	Unknown at this time.	Express Scripts

Misrepresentation	Approx. Date	Source	Recipient	Basis That Statement Is False ^{2, 3}	Reliance (if any)	Defendant(s) ⁴
for the at-issue drugs by soliciting competing rebate offers.		Sens. Grassley and Wyden	and Wyden; public statement	<i>Investigation; Priced Out of a Lifesaving Drug; Industry Spending Report; Sanofi memorandum on Basaglar pricing (COMPLAINT ¶ 397 (Fig. 25)); Sanofi presentation on formulary threats to Lantus (COMPLAINT ¶ 402 (Fig. 27)); Shepherd; Fein; Percher, supra; Written testimony of Doug Langa, U.S. H.R. Comm. on Energy and Commerce, “Priced Out of a Lifesaving Drug: Getting Answers on the Rising Cost of Insulin (Apr. 10, 2019); Balto Testimony.</i>		

22. In the form of the table below, describe any omissions that a Defendant allegedly made that forms the basis of the allegations in Your lawsuit, of which You are currently aware, including the approximate date, any statement to which the omission relates, the reason why You believe a Defendant should have disclosed the omission, and the Defendant(s) that made the omission:

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The list prices for the at-issue drugs are artificially inflated with kickbacks (“fees,” “discounts,” “credits,” etc.) that are mislabeled rebates that should be passed through to payors.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere that all rebates are passed through to payors; price inflation is not due to rebates; payments in question are actually “discounts,” “credits,” “fees”; PBMs honor price transparency; all rebates are subject to audit; payors are not injured by skyrocketing prices; payors are to blame for skyrocketing prices; and the pricing for the at-issue drugs is transparent.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants.

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The Manufacturers engage in shadow pricing.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere reflecting that pricing is transparent; pricing is competitive pricing; Defendants work to keep prices low for clients.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	Eli Lilly, Novo Nordisk, Sanofi.

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The PBMs grant Manufacturers preferred formulary coverage in exchange for rebates.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere reflecting that PBMs design formularies to promote health, cost-effectiveness/affordability, and access to diabetes and other medications.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
Express Scripts, CVS, and OptumRx use formulary exclusions and threats of formulary exclusions and preferred formulary status to extract greater rebates and keep list prices high.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere regarding formulary management, physician/panel formulary review, resulting cost savings to clients and patients, and access to medications.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	Express Scripts, CVS, OptumRx.

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The Manufacturers adjust prices in keeping with the PBMs' interests.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere reflecting that pricing is transparent; pricing is competitive pricing; Defendants work to keep prices low for clients.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The rising prices of insulins and GLP-1s hurt payors.	Throughout the relevant period	Rising prices of these medications hurt only patients, particularly uninsured and high-deductible patients; 100% of rebates are passed through to payors; payors are to blame for rising prices.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The PBMs use rebate aggregators to obscure the total rebates paid to the PBMs.	Throughout relevant period	Various representations above, cited in Complaint, and elsewhere that all rebates are passed through to payors; price inflation is not due to rebates; payments in question are actually “discounts,” “credits,” “fees”; PBMs honor price transparency; all rebates are subject to audit.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	Express Scripts, CVS, OptumRx.

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
Eli Lilly's generic version of Humalog, "Insulin Lispro," would be excluded from PBM formularies.	March 2019	Eli Lilly would produce Insulin Lispro and make it available at half the price of Humalog, with the goal of making insulins more affordable.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to the Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	Eli Lilly, CVS, OptumRx, Express Scripts

Omission	Approximate Date	Related Statement	Basis for Disclosure	Defendant(s)
The Manufacturers increase rebate offers, leading to higher list prices, in order to block competitors from the PBMs' formularies.	Throughout the relevant period	Various representations above, cited in Complaint, and elsewhere that rebates are not connected to rising list prices; pricing is transparent; formularies are designed to optimize health benefits and cost-effectiveness.	To the extent a duty to disclose is required, (1) the PBMs have superior knowledge, and information is not readily available to Plaintiff, and PBMs knew it; (2) necessary to clarify a partial or ambiguous statement; (3) fiduciary duty.	All Defendants

VIII. TIMING OF AWARENESS

23. Identify when and how You first learned or discovered that the prices for the At-Issue Products were allegedly artificially inflated, false, fraudulent, misleading, or deceptive:

Objection. Plaintiff objects that this question calls for information protected by the attorney client privilege. Subject to and without waiving this objection Plaintiff responds: To the best of its recollection, on or about August 2024 Plaintiff learned or discovered that the prices for the At-Issue Products were artificially inflated, false, fraudulent, misleading or deceptive through Plaintiff Representatives.

24. Identify the earliest date on which You began investigating the pricing of Defendants' At-Issue Products for the purpose of bringing the present action:

To the best of its recollection, on or about August 2024 Plaintiff began investigating the pricing of Defendants' At-Issue Products for the purpose of bringing the present action.

25. Identify when You first learned or discovered that Defendants' statements about the prices for the At-Issue Products were allegedly false, fraudulent, misleading, or deceptive:

To the best of its recollection, on or about August 2024 Plaintiff learned or discovered that Defendants' statements about the prices for the At-Issue Products were false, fraudulent, misleading or deceptive.

26. Describe how You first learned or discovered that Defendants' statements about the prices for the At-Issue Products were allegedly false, fraudulent, misleading, or deceptive:

Objection. Plaintiff objects that this question calls for information protected by the attorney client privilege. Subject to and without waiving this objection Plaintiff responds: Through conversations with Plaintiff Representatives.

27. Identify when and how You learned of or discovered any other lawsuit filed against any Defendant related to insulin pricing, including *In re Insulin Pricing* (D.N.J., 2:17-cv-00699), *MSP LLC* (D.N.J., 2:18-cv-02211), *Minnesota* (D.N.J., 2:18-cv-14999), and *In re Direct Purchaser Insulin Pricing Litigation* (D.N.J., 3:20-cv-03426):

Objection. Plaintiff objects that this question calls for information protected by the attorney client privilege. Subject to and without waiving this objection Plaintiff responds: To the best of its recollection on or about August 2024 Plaintiff learned of other lawsuits filed against any Defendant related to insulin pricing through Plaintiff Representatives.

28. Identify when and how You learned of or discovered any state, or federal investigation related to insulin pricing:

Objection. Plaintiff objects that this question calls for information protected by the attorney client privilege. Subject to and without waiving this objection Plaintiff responds: To the best of its recollection, on or about August 2024 Plaintiff learned of state and/or federal investigations related to insulin pricing through Plaintiff Representatives.

IX. SELECTION OF PRESCRIPTION DRUG COVERAGE

29. In the form of the table below, identify any third-party services, advisors, consultants, or contractors used by You to provide consulting, research, analysis, accounting, financial advice, solicitation, selection, development, or other advice related to Your Health Plan, selecting or soliciting PBM services, or Prescription Drug Coverage for At-Issue Products during the Time Period, the approximate dates You used the third-party services, advisors, consultants, or contractors, a description of the services that entity provided You, and the principal point of contact at the entity who is or was responsible for overseeing performance of the contract:

Third-Party Advisor (Advisor Name and Employer)	Approximate Dates	Description of Services	Point of Contact

30. For each third-party service, advisor, consultant, or contractor You identified in Question No. 29, in the form of the table below or through the production of documents, identify whether You received any presentations, reports, analyses, or memoranda related to Health Plan or Prescription Drug Coverage benefits designed for At-Issue Products, and produce those materials:

Unknown at this time but Plaintiff reserves the right to supplement this response.

Third-Party Advisor	Received Presentations, Reports, Analyses, Memoranda (Yes/No)

31. Did You or anyone acting on Your behalf conduct a request for proposal (“RFP”) or similar process to solicit offers from or to otherwise identify PBMs to administer Prescription Drug Coverage? ____ Yes ____ No

Unknown at this time but Plaintiff reserves the right to supplement this response.

If yes, in the form of the table below, identify each RFP or other solicitation You made during the Time Period, any third-party advisor that assisted with the RFP or solicitation, the PBMs You sent the RFP or solicitation to, and produce the RFP responses:

RFP or Solicitation	Third-Party Advisor	Date	PBMs Solicited

32. Are Your Health Plan expenditures related to pharmaceuticals audited, either internally or by an external auditor? ____ Yes ____ No

If yes, in the form of the table below, identify each audit and produce the audit:

Audit	Person or Entity conducting the Audit	Date	Purpose of the audit

X. MEMBERSHIP IN OTHER ENTITIES

33. In the form of the table below, identify any organizations that You are a part of that share information regarding at-issue insulins, pharmaceutical pricing, Rebates, PBM or drug pricing reform or legislation, including, but not limited to, the National Association of Counties, MMCAP, or any other group purchasing organization, and identify any of Your employees who are involved in that organization:

Organization	Dates of Membership	Your Involved Employees

XI. DIRECT PURCHASING

34. Have You purchased At-Issue Products directly from pharmaceutical manufacturers, wholesalers, mail order pharmacies, and/or retail sellers? ____ Yes X No

If yes, in the table below, identify each At-Issue Product You allege You purchased directly, the specific years You made the direct purchase, the entity that directly distributed the At-Issue Product(s) to You, the total quantity of At-Issue Products You purchased, and the total amount You paid:

At-Issue Product	Year	Direct Seller	Total Quantity	Total Amount Paid

XII. DAMAGES

35. For each Defendant identified in Question No. 4, in the form of the table below, state how You claim You have been damaged by that Defendant's alleged conduct. This request is not designed to require an expert evaluation:

Defendant	Basis
All Defendants	<p>Plaintiff has incurred and continues to incur direct and indirect monetary costs and harms as a result of Defendants' misconduct.</p> <p>The direct monetary costs and harms include <i>inter alia</i> (i) the increased costs Plaintiff has paid and continues to pay for the artificially inflated prices for the at-issue drugs as a result of Defendants' misconduct, (ii) increased fees Plaintiff has paid and continues to pay PBM Defendants for their services as a result of all Defendants' misconduct, and (iii) the failure of the PBM Defendants to pass through the full amount of rebates they claim to provide to Plaintiff as a result of all Defendants' misconduct.</p> <p>The indirect monetary costs and harm include <i>inter alia</i> lost opportunity costs, reduced bargaining power, increased burden to employees and staff, and the inability to allocate resources to other programs and services provided by Plaintiff in its capacity as a government entity.</p> <p>Plaintiff also incorporates by reference the damages set forth in its complaint and in its initial disclosures.</p> <p>Both direct and indirect monetary costs and harms will be identified, specified, and quantified at trial, including based on discovery provided by Defendants, publicly available information, and fact and expert testimony.</p>

36. For each Defendant identified in Question No. 4, in the form of the table below, identify to the best of Your knowledge the date when You allege that You were first injured as a result of that particular Defendant's alleged conduct. This request is not designed to require an expert evaluation:

Defendant	Date
For all Defendants	<p>Because of Defendants' misconduct, Plaintiff cannot pinpoint a specific month and year when it first began to incur direct and indirect monetary costs described above in response to Question 35. As set forth in Plaintiff's complaint and in response to Questions 23-28 above, each Defendant failed to disclose material facts sufficient for Plaintiff to identify Plaintiff's injury, its cause, and other operative facts supporting its claims.</p> <p>However, as set forth in response to Questions 23-28, Plaintiff recently became aware of information regarding Defendants' misconduct. Based on a reasonable investigation and information and belief, the exact date Plaintiff first became injured as a result of Defendants' misconduct is the date of their first interaction(s) wherein Defendants inflated prices.</p>

37. Are You seeking any monetary damages? x Yes No

If yes, summarize the categories of damages or monetary relief that You allege:

Plaintiff seeks past and future damages and monetary relief. As set forth in response to Question 35, Plaintiff seeks direct and indirect monetary costs it has paid and will continue to pay as a result of Defendants' misconduct. Plaintiff also seeks statutory damages and relief that are monetary in nature pursuant to its RICO, Antitrust, and state claims. Plaintiff also seeks injunctive relief to ensure that prices for at issue drugs remain appropriately priced prospectively.

INITIAL DOCUMENT REQUESTS

Please produce the following documents for the Time Period:

1. Each RFP seeking PBM services, including all amendments, riders, schedules, supplements, instructions, or other addenda that You issued during the Time Period.
2. Documents, including internal summaries, analyses, and presentations, reflecting Your reasons for selecting or not selecting a PBM prescription drug benefit plan for each year, including bids, communications, RFPs, procurement rules, guidance documents, and related documents, and documents relating to negotiation for Rebates for Your employee plan(s) or for Medicaid.
3. Each contract, including amendments, riders, schedules, supplements, or other addenda that You entered into with a PBM, health insurer, third-party administrator, or any other entity through which You obtained price concessions during the Time Period (e.g., MMCAP), or that otherwise was in effect during the Time Period.
4. Documents sufficient to identify the formularies for Your Health Plans during the Time Period.
5. For each benefit year for which You are seeking relief, documents relating to Your Health Plans, including documents sufficient to show: (1) the annual deductible(s), including separate deductible amounts or requirements for use of in-network versus out-of-network pharmacies, and any separate deductible amounts or requirements on individual versus family expenditures, (2) the copayment or coinsurance rate for each pharmaceutical tier, (3) the annual Out-of-Pocket Maximums, (4) the summary plan description, and (5) summaries of benefits and coverage associated with each of Your Health Plans during the time period.
6. Documents received by You that related to representations made by PBMs about their services or made by pharmaceutical manufacturers about their list prices.
7. Contracts with third-party advisors or auditors in effect during the Time Period that relate to prescription drug benefits, as well as any presentations, reports, analyses, or memoranda relating to prescription drug benefits Plaintiffs chose or did not choose.

CERTIFICATION

I declare under penalty of perjury that all of the information provided in this PFS is complete, true, and correct to the best of my knowledge and information, and that I have provided all of the requested documents that are reasonably accessible to me and/or my attorneys, to the best of my knowledge.

B. Fidd
Signature

2/21/25
Date

Brian Fidd
Name (Printed)

Superintendent
Title